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“Mesmo quando tudo parece desabar,  
cabe a mim decidir entre rir ou chorar, 
 ir ou ficar, desistir ou lutar.  
Porque descobri, no caminho incerto da vida,  
que o mais importante é o decidir” 
Cora Coralina 
(1889-1985) 
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Abstract 
 
New findings in stem cell research show that it is possible to reprogram a somatic 
cell into a pluripotent stem cell, by delivering specific genes. The induction of 
pluripotency arouse questions related with the possibility of directly reprogram a somatic 
cell into another somatic cell type, also by delivering specific combinations of genes, 
without going through a pluripotency state. 
 Several reports have shown that this direct conversion is possible and in 2010, the 
first description of the conversion of mouse fibroblasts into induced neuronal (iN) cells 
was published. Since then, it has been established that it is possible to obtain subtype 
specific iN cells from human fibroblasts.  
This thesis describes a project with the aim of directly convert human fibroblasts 
into striatal GABAergic projection neurons, by using a combination of defined 
transcription factors with important biological functions in neuronal development and 
differentiation of striatal neurons. Since these neurons are specially affected in cases of 
Huntington’s disease and stroke, their generation through the direct conversion process 
would possibly be a valuable approach to obtain cells that could be used in cellular 
therapy, being transplanted into patients’ brains.  
In order to maximize the efficiency of neural conversion, a comparative study 
including several protocols for the generation of iN cells was also performed.  
_________________________________________________________________________ 
 xiv 
Resumo 
 
Novas descobertas na área de investigação em células estaminais demonstram ser 
possível reprogramar uma célula somática numa célula pluripotente, através da entrega de 
genes específicos. Esta indução de pluripotência levantou algumas questões relacionadas 
com a possibilidade de converter directamente um determinado tipo célula somática 
noutro, também através da entrega de combinações específicas de genes, sem que esta 
célula passe por um estado de pluripotência. 
Várias publicações demonstraram que esta conversão directa é possível e em 2010, 
a primeira descrição da conversão de fibroblastos de rato em células neuronais induzidas 
foi publicada. Desde então, foi estabelecido também que é possível obter células neuronais 
induzidas, de um determinado sub-tipo, a partir de fibroblastos humanos. 
Esta tese descreve um projecto que teve como objectivo converter directamente 
fibroblastos humanos em neurónios GABAérgicos estriatais, utilizando uma combinação 
de factores de transcrição, com funções biológicas relacionadas sobretudo com o 
desenvolvimento neuronal e a diferenciação de neurónios estriatais. Pelo facto de estes 
neurónios serem especialmente afectados em casos de doença de Huntington e acidente 
vascular cerebral, a sua obtenção através de um processo de conversão directa constituiria 
um método de grande valor para a obtenção de células que poderiam ser utilizadas em 
terapia celular, servindo como material de transplante em cérebros de pacientes. 
De modo a maximizar a eficiência da conversão neuronal, um estudo comparativo 
envolvendo diferentes protocolos para a obtenção de células neuronais induzidas foi 
também realizado.  
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 3 
1.1 Stem cells  and regenerative medicine in the central  nervous 
system 
 
 Ever since Santiago Ramon y Cajal, the famous anatomist, wrote in the early 20th 
century that the central nervous system (CNS) does not regenerate once it is injured 
(Ramon y Cajal and May, 1928), this theory has been in fact accepted. Actually, there is a 
lack of regenerative properties from the CNS that may be attributable to several factors. It 
can be observed, for example, during a spinal cord injury, in which the inhibitory 
character of the CNS myelin and injury-induced glial scars, the apparent inability of 
endogenous adult neural stem cells (NSCs) in the spinal cord to induce de novo 
neurogenesis upon injury (Johansson et al., 1999), and the lack of sufficient trophic 
support (Widenfalk et al., 2001), can difficult regeneration. 
 
The use of transplantation as a therapeutic approach to repair the brain and spinal 
cord has the specific goals of providing new neurons that either functionally reconstruct 
neural circuits, produce neurochemically active substances (neurotransmitters, growth 
factors, antibodies, or growth substrates), or remyelinate axons (Okano, 2002).  
 
 Decades later, some studies reported a promising and successful transplantation of 
peripheral nerves (Richardson et al., 1980) and fetal spinal cord (Bregman, 1987), that 
indicated that by introducing an appropriate environment into the injured site could cause 
injured axons to regenerate. Spinal cord regeneration is also described by other reports, 
including the promotion of the regeneration of injured axons by neurotrophic factors (Cai 
et al., 1999), and the identification of axonal growth inhibitors (Chen et al., 2000).  During 
the late 1980’s, studies involving the transplantation of human fetal mesencephalic tissue, 
obtained from aborted fetuses, to the striatum of Parkinson’s disease (PD) patients were 
started. These grafts were able to survive and to induce symptomatic relief in some 
patients, reinnervating the striatum, releasing neurotransmitters and becoming integrated 
in the patient’s brains (reviewed in (Lindvall and Bjorklund, 2004)). These findings 
opened a new era for regenerative medicine in the brain. However, although the feasibility 
of this technique has been demonstrated, its practical clinical application has found some 
technical barriers due to the small number of donor cells, the large variation in outcome 
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and adverse effects such as graft-induced dyskinesias in some patients (Bjorklund et al., 
2003; Freed et al., 2001; Olanow et al., 2003; Winkler et al., 2005). 
 
Stem cells are an unique type of cell that can be distinguished from the other body 
cells because of three major characteristics: a) they are undifferentiated and unspecialized; 
b) they have self-renewing and indefinitely division capacities; and c) they are able to 
become specialized into all cell types of the human body, from the three different germ 
layers (endoderm, mesoderm and ectoderm) (Verfaillie et al., 2002).  
 
Stem cell self-renewal is the consequence of a particular cell division that takes 
place within a special microenvironment where stem cells reside, the niche. In the niche, 
the stem cells division can result in a progenitor daughter and in a daughter that remains a 
stem cell (asymmetric division) or in two stem cell daughters (symmetric division). 
Asymmetric stem cell division contributes to the correct replacement of daughter cells 
inside and outside the niche. Then, when subjected to specific molecular signals, 
progenitor cells generate a differentiated progeny (Cheng et al., 2008; Cowan and Hyman, 
2004; Gaziova and Bhat, 2007; Rusan and Peifer, 2007; Segalen and Bellaiche, 2009; Tulina 
and Matunis, 2001; Yamashita, 2009; Yamashita and Fuller, 2008; Yamashita et al., 2005; 
Yamashita et al., 2007).  
 
Stem cell-based replacement therapies, in which these cells are used as transplant 
material, are considered as an emerging powerful tool for regenerative medicine. Due to 
their regeneration properties, stem cells evoke a solid enthusiasm in the medical 
investigation field and allow predicting several therapeutic applications, including for 
neurodegenerative diseases (Orlacchio et al., 2010).  
 
The term neurodegenerative disease is used for a wide range of either acute or 
chronic conditions, in which neurons and glial cells in the brain and spinal cord are lost.  
In the case of acute conditions, as a response to an ischemic stroke or a spinal cord injury, 
different types of neurons and glial cells die within a restricted area of the brain over a 
short period time. In chronic conditions, there is either a selective loss of a specific cell 
population, such as dopamine (DA) neurons in PD and motor neurons in amyotrophic 
lateral sclerosis (ALS), or a widespread degeneration of many types of neurons, such as the 
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one occurring in Alzheimer’s disease (AD), over a period of several years (Lindvall and 
Kokaia, 2010). 
 
According to its origin and differentiation capacity, several types of stem cells are 
considered to be interesting in the field of regenerative medicine. Each stem cell type 
possesses certain qualities and advantages, and the rationale for utilizing each depends on 
the desired applications and outcomes. Similarly, each set of stem cells is associated with 
its own set of problems as well. 
 1.1.1 Embryonic stem cells  
At the 4th day after fertilization, the cells resulting from the divisions of the recently 
formed egg (totipotent cells) start to become specialized forming the blastocyst, from 
which it is possible to remove the cells present in its internal layer. Those cells are capable 
to origin any kind of tissue in the organism, of any of the three primary germ layers as well 
as the primordial germ cells, except the extra-embryonic structures (placenta and 
supporting tissues of the uterus) (Fischbach and Fischbach, 2004; Wobus and Boheler, 
2005). These pluripotent cells are known as embryonic stem cells (ESCs). 
 
ESCs have the ability to perpetually self-renew in culture and maintain 
undifferentiated phenotype, as well as a normal karyotype (Gage et al., 1995). The 
establishment of human ESCs (hESCs) from in vitro fertilized embryos (Thomson et al., 
1998) and the demonstration of their developmental potential in vitro (Schuldiner et al., 
2001; Thomson et al., 1998) have evoked widespread discussions concerning future 
applications of hESCs in regenerative medicine. Therefore, they were seen as excellent 
candidates for using as a source of neurons during the treatment of neurological disorders 
(Thomson et al., 1998).  
 
However, the use of these cells has been associated with their own set of problems. 
A major hurdle is related to problems in generating large and defined populations of the 
desired types of neurons from hESCs (Li et al., 2008). Also, a good cell survival of the graft 
is essential for the effectiveness of the transplant during the treatment of those 
neurological disorders (Hagell and Brundin, 2001). A poor survival of the grafted cells was 
observed in some studies, which was explained by the possibility of those cells being 
relatively mature when harvested from culture (Freeman and Brundin, 2006), suggesting 
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that their maturation has passed a narrow optimal time window at the time of harvesting. 
Thus, a balance in the percentage of differentiation of the transplanted cells is needed. 
 
 
Figure 1 – Stem cell  therapy for CNS disorders using hESCs.  
Five days after fertilization, it is possible to remove the cells present in the internal layer of the 
recently formed blastocyst. From these cells, ESCs, neural precursors (neural stem cells) can be 
obtained (among others, as cardiac, muscle and blood precursors), expanded through neurosphere 
formation and differentiated into neurons that could be used for cell therapy purposes in 
neurodegenerative diseases’ treatment.   
 
While the excessive maturation of the cells is not advantageous, the excess of 
undifferentiated cells also brings up the risk of tumor formation after transplantation (Li 
et al., 2008). The delineation of the optimal developmental stage of transplanted cells 
remains a key issue. Candidate cells should be committed to their target specialization but 
must retain the plasticity of their precursors that is necessary for effective integration in 
the CNS (Einstein and Ben-Hur, 2008). 
 
Even if the cell survival of the graft is optimal, another issue that can affect ESC-
derived cell transplantation is the immune rejection of the grafts. Although the brain is 
considered to be an immune-privileged transplantation site (Li et al., 2008), strong 
immune responses occur in the brain in neurodegenerative disorders (Nguyen et al., 2002) 
or after intra-cerebral neural transplantation (Barker and Widner, 2004; Krystkowiak et 
al., 2007). Consequently, allogeneic cells and animal-derived products used during in vitro 
differentiation of the cells might trigger immune reactions and lead to graft rejection 
(Martin et al., 2005). Immunosuppressive treatments are used, but they do not fully 
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prevent chronic rejection and the risk of opportunistic responses increase (Brimble et al., 
2004; Lopez et al., 2006). Another strategy is the generation of stem cells that are perfectly 
genetically matched to the host and can be generated by somatic nuclear transfer, also 
named therapeutic cloning (Barberi et al., 2003; Hipp and Atala, 2004). These cells would 
be identical to the recipient except for the proteins encoded by the mitochondrial genome. 
More recently, induced pluripotent stem cells (iPSCs), discussed in section 1.1.3, have 
become a possibility to generate genetically matched cells for transplantation. 
 
The use of ESCs has also been strongly controversial due to the political, religious 
and ethical implications about the use of human embryos for their obtention. 
 
Despite their use in transplantation therapy, ESCs remain as valuable research 
tools, namely for understanding the gene function in mammals, unlocking the function of 
many genes in normal development, normal physiology, and disease pathogenesis. The 
ability to create specific disease models was also considered as a possibility while using 
these cells, enabling drug screening on proximate models of human disease rather on 
animal surrogates (Verfaillie et al., 2002). 
 
1.1.2 Neural stem cells  
 As the pluripotent cells become more specialized, they form specific tissues, and 
their differentiation potential becomes more restrict, so they can be called multipotent 
(Santner-Nanan et al., 2005; Verfaillie et al., 2002). In the adult organism it is possible to 
isolate multipotent stem cells from several tissues, such as: bone marrow, blood, adipose 
tissue, dental bulb and also from the skin, liver, pancreas and other organs. Those non-
embryonic cells are somatic or adult stem cells (ASCs) and they are likely to replenish cells 
that are lost by physiological turnover, as well as pathological conditions including injury 
and degenerative diseases (Okano, 2002). 
 
 It has long been believed that stem cells are not present in the adult mammalian 
CNS, but many lines of recent evidence have shown that stem cells do exist in the adult 
brain and that they are self-replicative, as well as able to give rise to differentiated progeny 
(neurons, astrocytes and oligodendrocytes) in vitro and in vivo (Doetsch et al., 1999; 
Johansson et al., 1999; Kempermann and Gage, 1999; Morshead et al., 1994; Reynolds and 
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Weiss, 1992; Temple and Alvarez-Buylla, 1999). Those stem cells are known as neural 
stem cells (NSCs) and their multilineage potential is at least partially mediated by the 
generation of cell lineage-restricted intermediate progenitor cells that produce only 
neurons (neuronal progenitor cells (NPCs)) and glial progenitor cells that produce only 
astroglial or oligodendroglial cells (Luskin et al., 1988; Qian et al., 2000).  
 
 Although these stem cells have the ability to give rise to the three types of cells 
composing the CNS, it seems that the endogenous brain environment that is responsible 
for such differentiation process is not adequate and gives rise to a limited capacity of 
repair in the adult CNS of patients suffering from injury or diseases (Bjorklund and 
Lindvall, 2000).  
  
During the last years, continuously dividing immortalized cell lines of NSCs have 
been generated by introduction of oncogenes, and these immortalized lines have 
advantages for basic studies of neural development and cell replacement therapy or gene 
therapy studies (Flax et al., 1998; Hoshimaru et al., 1996; Kim, 2004; Kim et al., 2008; Lee 
et al., 2007; Renfranz et al., 1991; Snyder et al., 1992). Cell replacement and gene transfer 
to the diseased or injured CNS with NSCs have provided the basis for the development of 
potentially powerful new therapeutic strategies for a broad spectrum of human 
neurological disorders including PD, AD, ALS, stroke, spinal cord injury and brain 
tumors (Brustle and McKay, 1996; Flax et al., 1998; Gage, 2000; Goldman, 2005; Gottlieb, 
2002; Kim, 2004; Lindvall et al., 2004; McKay, 1997; Temple, 2001). It has also become 
clear that the characteristics of the pathological environment, such as the magnitude of 
inflammation, play a crucial role in the survival, differentiation, and function of both 
grafted and endogenous cells (Becker et al., 2007; Biscaro et al., 2009; Di Giorgio et al., 
2007; Hoehn et al., 2005; Lepore et al., 2008; Liu et al., 2007; Marchetto et al., 2008; Thored 
et al., 2009). 
 
One of the major breakthroughs of the CNS stem cell biology was the 
establishment of clonogenic expansion of NSCs by neurosphere formation (Reynolds and 
Weiss, 1992), which enabled the definition of NSCs experimentally and the quantification 
of the multilineage potency and self-renewing ability of these cells. Using this culture 
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method, NSCs can proliferate in an undifferentiated state in vitro, allowing them to be 
expanded mitotically and harvested in bulk. 
 
By taking advantage of the ease of NSCs harvesting after expansion in vitro by 
neurosphere formation (or similar methods), there have been numerous attempts to 
transplant NSCs into animals to treat damaged brains and spinal cords (Ogawa et al., 
2002; Studer et al., 1998; Svendsen et al., 1996).  
 
The mechanisms of action of stem cells and their progeny underlying behavioral 
recovery in animal models are better understood than they were just a few years ago 
(Lindvall and Kokaia, 2010). Besides cell replacement, stem cells are known to lead to 
improvements that could also be of clinical value through immunomodulation, trophic 
actions, neuroprotection, and stimulation of angiogenesis (Corti et al., 2007; Hwang et al., 
2009; Kerr et al., 2003; Klein et al., 2005; Pluchino et al., 2005; Suzuki et al., 2007; Xu et al., 
2009; Xu et al., 2006). 
 
1.1.3 Induced pluripotent stem cells   
Among some of the most relevant findings in the field of stem cell biology 
research, the possibility of reprogramming somatic cells to a pluripotent ESC-like state, by 
forcing the cells to express genes and factors important for maintaining pluripotency and 
to differentiate into cells of all three germ layers was absolutely stunning.  
 
By using only four transcription factors (TFs) (Oct3/4, Sox2, Klf4 and c-myc) 
Takahashi and colleagues have demonstrated that somatic mouse cells (embryonic and 
adult) may be reprogrammed into induced pluripotent stem cells (iPSCs) (Takahashi and 
Yamanaka, 2006). Those factors function in the maintenance of pluripotency in both early 
embryos and ESCs (Oct3/4 and Sox2) (Avilion et al., 2003; Nichols et al., 1998; Niwa et al., 
2000) and are frequently upregulated in tumors, contributing to the long-term 
maintenance of the ESCs phenotype and their rapid proliferation in culture (c-myc and 
Klf4) (Cartwright et al., 2005; Li et al., 2005). The resulting iPSCs had many of the 
characteristics of mouse ESCs, but failed to contribute to chimeras at term, which is 
considered the gold standard criterion for a pluripotent stem cell population, and showed 
differences in gene expression and chromatin organization when compared with ESCs 
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(Thompson and Yin, 2010). One year later, the same research group was able to generate 
iPSCs that contributed to chimeras (Okita et al., 2007) and moreover, they translated those 
remarkable findings from mouse to human (Takahashi et al., 2007), transducing cultures 
of adult human fibroblast populations from different donors with retroviral vectors 
carrying transgenes for the human versions of Oct4, Sox2, Klf4 and c-myc (Figure 2), and 
after thirty days under human ESC culture conditions, the culture plates were covered 
with iPSCs (Takahashi et al., 2007). 
 
 
Figure 2 – Transcriptor factor-induced pluripotency.  
Adult fibroblasts obtained from human donors were exposed to retroviral vectors expressing a 
cocktail of four transgenes encoding the human factors hOct4, hSox2, hKlf4 and hc-myc. Thirty 
days after transduction and further cultivation under hESCs growth conditions, human iPSC 
colonies that could be propagated and further expanded were isolated. Comparative analysis of 
human iPSCs and hESCs using assays for morphology, surface-marker expression, gene expression 
profiling, epigenetic status and in vitro and in vivo differentiation potential revealed a remarkable 
degree of similarity between these two pluripotent stem cell types (image adapted from (Zaehres 
and Scholer, 2007).  
 
Yu et al., provided additional insight as to the mechanisms that induce 
pluripotency in human fibroblasts, in 2007, and also succeeded in reprogramming human 
somatic cells, but with a different cocktail of factors (Yu et al., 2007). Since the publication 
of comparable findings about human iPSCs underscores the validity of these cells and 
removes any doubt that their isolation might be irreproducible. 
 
The obtained iPSCs may be used for many applications, circumventing the 
problems that are associated with ethical issues regarding the use of human embryos for 
the obtention of ESCs, as well as the problem of tissue rejection after transplantation into 
patients, since they could be derived directly from the patient’s own somatic cells. Also 
due to its pluripotent characteristics, those cells could be used to generate other cell types, 
being a helpful tool in regenerative medicine (Takahashi and Yamanaka, 2006). In 
humans, many different cell types have been used for reprogramming into iPSCs, such as 
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keratinocytes, CD34+ hematopoietic stem cells, cord blood-derived endothelial cells, 
NSCs, amniotic fluid-derived cells, CD34+ peripheral blood cells, adult human adipose 
stem cells derived from lipoaspirate, among many others (reviewed in (Masip et al., 2010). 
 
Furthermore, in the near future, iPSCs can also be used as disease models, helping 
to elucidate disease mechanisms, study metabolic pathways and/or screen new drugs, as 
well as models for normal development, oncology and differentiation processes in humans 
(Masip et al., 2010).  
 
During development, the diverse cell types are defined by lineage-specific TFs that 
guide and reinforce cell type-specific gene expression patterns. Epigenetic modifications 
will further stabilize cellular phenotypes, allowing faithful transmission of cell-specific 
gene expression patterns over the lifetime of an organism (Bernstein et al., 2007; Jenuwein 
and Allis, 2001). Thus, the remarkable transformation of cells into a pluripotent state has 
been interpreted as a reversion of mature into more primitive developmental states, with a 
concomitant erasure of the developmentally relevant epigenetic information (Silva and 
Smith, 2008).  
 
Although iPSCs and ESCs are very similar, they are not identical, as previously 
shown by Takahashi et al. (Takahashi et al., 2006). They show differences in gene 
expression signatures, as also shown by Chin et al. (Chin et al., 2009), as well as differences 
in DNA methylation patterns (Deng et al., 2009), and the efficiency to differentiate to 
specific lineages has been reported to be superior in ESCs compared with iPSCs (Feng et 
al., 2010). 
 
Extensive tests will be required to confirm that the resulting cell lines are 
equivalent to those derived from embryos. Some authors also refer that would be a 
tremendous mistake to consider hESCs obsolete, since there are still many hurdles to 
overcome before we fully understand pluripotency and before obtaining human iPSCs that 
are suitable for therapeutic application. It has been demonstrated that mouse iPSC-
derived chimeras frequently develop tumors, resulting from the activation of the 
oncogenes c-myc and Klf4 (Kim et al., 2009; Markoulaki et al., 2009; Okita et al., 2007). 
The use of genome integrative methods, such as retroviral/lentiviral vectors, may also 
cause, by itself, tumor formation. Although the expression of encoded genes is silenced in 
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fully reprogrammed iPS cell lines with retroviral integrative methods (Hotta and Ellis, 
2008), and nearly complete silencing of lentiviral transgenes has been observed in the 
context of induced pluripotency (Ebert et al., 2009; Yu et al., 2007), the integrated foreign 
DNA remains in the genome and could disrupt/alter the host genome expression, causing 
tumor formation (Hochedlinger et al., 2005). Additionally, it has been proposed that 
residual transgene expression may explain some of the observed differences between ESCs 
and iPSCs, such as the altered differentiation into functional cell types (Soldner et al., 
2009; Yu et al., 2007). 
 
Despite all the questions that remain about iPSCs, reprogrammed cells have 
certainly a tremendous potential for new discoveries, which may help establish therapies 
for current and new diseases (Masip et al., 2010). 
 
1.2 Direct reprogramming, iN cells  and regenerative medicine in 
the central  nervous system 
 
1.2.1 Direct conversion, an old and new concept.  
Reprogramming of somatic cells by using viral vectors, has raised the question of 
whether reprogramming could be successfully achieved by directly converting one 
differentiated cell type into another. This so called direct conversion process or lineage 
reprogramming has received significant attention due to the possible applications for 
cellular therapy (Masip et al., 2010).  
 
In fact, several previous studies have shown the induction of direct conversion, 
generally within the same lineage, due to the ectopic overexpression of isolated factors. In 
1987, Davis et al., were able to convert fibroblast-like cells into stable myoblasts by 
transfecting a single myoblast-specific cDNA (myoD) (Davis et al., 1987), but the same 
was not possible when transfected cells were hepatocytes (Schafer et al., 1990). Since then, 
other remarkable examples of cell-fate reprogramming by defined factors have been 
reported: the overexpression of IL-2 receptor and granulocyte-macrophage colony-
stimulating factor receptor induced a myeloid conversion of committed lymphoid 
progenitor cells (Kondo et al., 2000); the expression of C/EBP alpha and beta in B cells 
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(Xie et al., 2004) as well as the overexpression of PU.I (also called Sfpi I) and transcription 
factors C/EBP alpha and beta in fibroblasts (Bussmann et al., 2009; Feng et al., 2008; Graf 
and Enver, 2009) induced macrophage differentiation. Moreover, the deletion of Pax5 can 
induce B cells to de-differentiate toward a common lymphoid progenitor (Cobaleda et al., 
2007).  
 
Significant evidence suggests that a specific combination of multiple factors, rather 
than a single one, may be the most effective tool to reprogram adult cells. Zhou et al. 
described the lineage reprogramming process in adult mouse pancreas from exocrine 
pancreatic cells to β-cells (Zhou et al., 2008) by adenoviral infection of three TFs (Ngn3, 
PdxI and Mafa) that are important in the embryonic development of the pancreas and β-
cells, which were narrowed down from nine genes exhibiting β-cell developmental 
phenotypes when mutated (Jensen, 2004; Murtaugh and Melton, 2003). In 2009, Takeushi 
and Bruneau described the transdifferentiation of mouse mesoderm to heart tissue by 
transient transfection of Gata4, Tbx5 and Baf60c in cultured mouse embryos (Takeuchi 
and Bruneau, 2009).  
 
It didn’t take long until several reports showed to be possible to generate several 
different cell types from fibroblasts, an easily obtained cell source. Cardiomyocytes, blood 
progenitor cells, hepatocytes, epiblast stem cells and neural progenitors (Efe et al., 2011; 
Han et al., 2011; Han et al., 2012; Huang et al., 2011; Ieda et al., 2010; Sekiya and Suzuki, 
2011; Szabo et al., 2010; Thier et al., 2012) were generated from mouse and human 
fibroblasts. 
 
Fibroblasts exist in the interstices of various organs as a component of connective 
tissue and are one of several types of somatic cells that have been well established in 
culture. Human fibroblasts were shown to be able to directly differentiate into all three 
germ layer derivatives, and there are studies that indicate that human dermal fibroblasts 
have more plasticity than has been generally thought and that they have potential utility as 
a source for cell therapy (Osonoi et al., 2011).  Therefore, the use of this cell source has 
become very common for cell reprogramming. 
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Some authors refer that it is not a surprise to verify that TFs are predominant in 
reprogramming experiments since they are the primary effectors of lineage decisions 
during normal development (Vierbuchen and Wernig, 2011). The use of other classes of 
factors, combined with TFs, is emerging though, as it will be further discussed. 
 
A TF can be defined as a protein that has the capacity to bind to specific DNA 
sequences, controlling the transcription of genetic information contained in the DNA to 
messenger RNA (mRNA) (Karin, 1990; Latchman, 1997). According to the kind of TF, the 
transcription of the adjacent gene can be either up- or down regulated, i.e., they can act by 
promoting (as an activator), or blocking (as a repressor) the recruitment of RNA 
polymerase (the enzyme that performs the transcription of genetic information from DNA 
to RNA) to specific genes (Lee and Young, 2000; Nikolov and Burley, 1997; Roeder, 1996). 
They perform this function alone or with other proteins in a complex and they use a 
variety of mechanisms for the regulation of gene expression (Gill, 2001) such as: 
stabilization or blockage of the binding of the RNA polymerase to DNA; catalyzation of 
the acetylation or deacetylation of histone proteins (involved in up- and down regulation 
of transcription, respectively); and recruitment of co-activator or co-repressor proteins to 
the TF DNA complex (Xu et al., 1999).  
 
 
Figure 3 – Schematic  representation of  the activity  of  a  transcription factor and 
its  domains.   
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A gene (gene X) is transcribed to form a strand of mRNA, which is then translated by the cellular 
machinery into a protein, the transcription factor (TF). The function of a TF, though, is to migrate 
back to the nucleus, and bind to specific regions of DNA, affecting the transcription of other genes 
(it will up- or down-regulate them). In this example, the TF X turns on genes A, B and D, and 
turns off gene C. The proteins A, B and D can also act like transcription factors and they can 
feedback on each other and on other transcription factors that are not directly regulated by gene X. 
In the dashed box, a schematic diagram of the aminoacid sequence of a prototypical transcription 
factor is shown. It contains: a DNA-binding domain (DBD); a signal-sensing domain (SSD) 
(which senses external signals and, in response, transmits these signals to the rest of the 
transcription complex, resulting in up- or down-regulation of gene expression); and a 
transactivation domain (TAD) (that contains binding sites for other proteins such as transcription 
coregulators) (adapted from http://scienceblogs.com/pharyngula/2006/07/09/transcription-
factors-and-morp/, as retrieved in 17 of June of 2012).  
 
1.2.2 Direct conversion and iN cells 
 In 2010, the direct reprogramming of somatic cells into nervous system cells 
(neurons) was described by Wernig and co-workers. Initially, 19 genes specifically 
expressed in neural tissues or implicated in neural development were screened. After the 
screening process it was established that only three factors (Ascl1, Brn2 and Myt1L, 
(ABM)) sufficed to convert mouse embryonic fibroblasts (MEFs), carrying a green 
fluorescent Tau protein (Tau-GFP) reporter, into functional induced neuronal (iN) cells. 
In order to evaluate whether iN cells could also be derived from postnatal cells, similar 
assays were performed with tail-tip fibroblasts, and the results were identical to those that 
were obtained with MEFs. Although the single factor Ascl1 was sufficient to induce 
immature neuronal features, the additional expression of Brn2 and Myt1L generated 
mature iN cells with efficiencies of up to 19.5%. The generated cells displayed functional 
neuronal properties such as the generation of trains of action potentials and synapse 
formation, and they were on its majority excitatory cells expressing markers of cortical 
identity. A low proportion of iN cells expressed markers of GABAergic neurons, but no 
other neurotransmitter phenotypes were detected (Vierbuchen et al., 2010). Later, the 
same group proved that by combining the ABM factors with NeuroD1, they could convert 
fetal and postnatal human fibroblasts into iN cells showing typical neuronal morphologies 
and expressing multiple neuronal markers (Pang et al., 2011). 
 
The combination of factors ABM by itself, also proved to be efficient in converting 
human embryonic and postnatal fibroblasts into mature human iN (hiN) cells (Pfisterer et 
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al., 2011a) as well as in converting adult human fibroblasts isolated from adult individuals, 
into functional hiN cells (Pfisterer et al., 2011b). In addition to these findings, Pfisterer 
and colleagues proved that by adding other TFs to the ABM cocktail they could generate a 
different neuronal type, as the dopaminergic (induced dopaminergic (iDA) neurons) 
(Pfisterer et al., 2011a). In order to prove this, they selected ten genes involved in midbrain 
patterning and specification of dopamine (DA) neurons, cloned them into lentiviral 
vectors and by infecting the fibroblasts with these lentiviruses, using different TF 
combinations, they found out that the highest numbers of tyrosine-hydroxylase (TH)-
positive cells could be detected when using the factors ABM supplemented with the factors 
Lmx1a and FoxA1. The iDA were able to generate action potential and to give rise to 
currents, showing to be functional hiN cells. These subtype-specific hiN cells could be a 
helpful tool for the study of a treatment of neurological diseases such as PD and may serve 
as an interesting alternative to iPSCs for generating patient- and/or disease-specific 
neurons.  
 
 
Figure 4 – Direct  reprogramming of  somatic  cel ls  into subtype-specif ic  neurons.   
The patient’s cells are collected and used for reprogramming, creating patient-specific neurons, 
without going through a pluripotent state. Thus, the generated cells are considered as syngeneic, 
which means that they are genetically identical and immunologically compatible to allow for 
transplantation. 
 
Several groups have now shown different cocktails of transcription factors and 
other molecules as being able to directly convert mouse and human fibroblasts into iN 
cells, also including dopaminergic and motor neurons, and even showing it to be possible 
to convert other terminally differentiated cell types into neurons. Table I shows some of 
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the most recent and relevant reports, describing the generation of these iN cells. Other 
classes of factors, such as components of chromatin modifying complexes, small 
molecules, microRNAs (miR) and other RNA species could also be able to induce lineage 
conversion, as described in some of the studies presented below. 
 
Table I  –  Recent f indings in iN cel ls ’  generation. 
Factors 
used Reprogrammed from: 
Identity of the generated 
cells confirmed by: 
“Direct  conversion of  f ibroblasts  to functional neurons by defined factors”,  (Vierbuchen et  
al . ,  2010) 
ABM Mouse embryonic and postnatal fibroblasts Mouse postnatal fibroblasts 
Immunocytochemistry 
Electrophisiology 
“Direct  conversion of  human fibroblasts  to dopaminergic  neurons”,  (Pfisterer et  al . ,  2011a)  
ABM 
ABM + Lmx1a 
and FoxA2 
Human embryonic fibroblasts 
Human postnatal fibroblasts 
Immunocytochemistry 
Electrophysiology 
“Direct  generation of  functional dopaminergic  neurons from mouse and human fibroblasts” ,  
(Caiazzo et  al . ,  2011) 
Ascl1, Nurr1 
and Lmx1a 
Mouse embryonic fibroblasts 
Human fetal fibroblasts 
Human adult fibroblasts (from healthy and 
PD patients) 
Immunocytochemistry 
qPCR Global expression analysis  
High-performance l iquid 
chromatography 
Electrophysiology 
Amperometry 
In vivo  differentiation assays  
In vivo electrophysiology 
“MicroRNA-mediated conversion of  human fibroblasts  to  neurons” ,  (Yoo et  al . ,  2011) 
miR-9/9*, miR-
124, NeuroD2, 
Asc1 and Myt1L 
Human neonatal fibroblasts 
Human adult fibroblasts 
Immunocytochemistry 
Electrophysiology 
Single-cell  qPCR 
"Induction of  human neuronal cel ls  by defined transcription factors” ,  
 (Pang et  al . ,  2011) 
ABM and 
NeuroD1 
hESCs 
Human fetal fibroblasts 
Immunocytochemistry 
Single cel l  RT-PCR 
Electrophysiology 
“Conversion of  mouse and human fibroblasts  into functional spinal  motor neurons” ,  
 (Son et  al . ,  2011)  
ABM + Lhx3, 
Hb9, Isl1, Ngn2 
and NeuroD1 
 
Mouse embryonic fibroblasts 
Human embryonic fibroblasts 
Immunocytochemistry 
FACS and qRT-PCR 
Electrophysiology 
In vivo  transplantation 
“Direct  l ineage conversion of  terminally  dif ferentiated hepatocytes  to functional neurons” ,  
(Marro et  al . ,  2011) 
ABM Mouse embryonic fibroblasts Postnatal hepatocytes 
Immunocytochemistry 
qRT-PCR and FACS 
Electrophisiology 
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“Small  molecules  enable highly ef f icient neuronal conversion of  human fibroblasts” ,  
(Ladewig et  al . ,  2012) 
Ascl1 and Ngn2 
(AN) 
+ 
SB-431542 
Noggin 
CHIR99021 
Human postnatal fibroblasts 
Cord blood-derived stem cells (CB-SCs) 
Adult human fibroblasts (healthy donor) 
Immunocytochemistry 
Gene expression array 
Electrophysiology 
 
Other reports have also shown to be possible to generate iDA cells by using 
different combinations of TFs (Kim et al., 2011; Liu et al., 2012). A report describing the 
direct reprogramming of AD patient cells into functional neurons (Qiang et al., 2011) was 
also published. And additionally, another report showed to be possible to reprogram 
postnatal astroglia of mouse neocortex into functional, synapse-forming neurons 
(Heinrich et al., 2012). 
 
The use of small molecules (SM) to enhance conversion of the cells into the desired 
phenotype had gained some attention when Ladewig et al. (Table I) described the highly 
efficient neuronal conversion of human fibroblasts into neurons. Initially, they used 
human postnatal fibroblasts, and infected these cells with Ascl1 and Neurogenin2 (Ngn2) 
(AN), which was the combination of factors that gave rise to the highest portion of βIII-
tubulin. A synergistic SMAD pathway inhibition (dual SMAD inhibition) was used in 
their protocol, by applying the activin-like kinase 5 inhibitor SB-431542, together with 
Noggin. Additionally, inhibition of the glycogen-synthase kinase-3β (GSK-3β) was also 
used, through the application of the CHIR99021 inhibitor (Ladewig et al., 2012). The 
inhibition of SMAD signaling and of the GSK-3β have been used for highly efficient 
neural differentiation of hESCs and iPSCs ((Chambers et al., 2009; Li et al., 2010)). By 
doing so, Ladewig and colleagues were able to generate neurons with different 
neurotransmitter phenotypes, in very high yields and with high purities (Ladewig et al., 
2012).  
 
The fact that different combinations of TFs can drive the same cell fate conversion 
process suggests that many (if not all) of the key upstream TFs regulate one another 
(Vierbuchen and Wernig, 2011). Such variability in factors’ combination and applications 
shows that neuronal conversion is feasible and reproducible under different conditions. 
However, the exact differences between the generated cells, obtained from different 
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combinations of factors, or between the generated cells and their target cells counterparts 
are still not completely addressed. Some evidence also suggests that the generated iN cells 
show differences in gene-expression, when compared with primary cells (Caiazzo et al., 
2011). 
 
It also remains unclear whether the direct lineage conversions fully reprogram the 
cells, or if any epigenetic memory of the previous cell fate remains. It is still not known if 
the intrinsic gene expression network is similar in reprogrammed cells and in 
differentiated cell types or if these networks are triggered during reprogramming. To 
answer this question, another one arises, concerning the fact of whether all the 
characteristics of the reprogrammed cells are maintained upon withdrawal of the inducing 
factors or not (Chambers and Studer, 2011). Experiments involving DNA excision or 
nonintegrating gene delivery have demonstrated that, for many passages, iPSCs maintain 
expression of pluripotent markers, differentiation capacity and epigenetic state in the 
absence of reprogramming factors (Hanna et al., 2010). This stability was associated with 
the induction of the intrinsic feedforward network of factors controlling pluripotency 
(Boyer et al., 2005). Furthermore, the way similarities and differences between converted 
cells and primary neurons, in terms of gene expression and chromatin structure, correlates 
with their functionality (neurotransmitter production, firing of action potentials and 
functional integration into neural networks) of the reprogrammed neurons, is a question 
that should also be addressed. 
 
Since miRs and TFs affect the expression of other proteins involved in cell-fate 
switching and neuron differentiation, further work should access how the various 
chromatin-remodeling factors can affect gene expression, contribute to cell conversion 
and how can they be controlled (Sendtner, 2011).  
 
The impact that the donor cell types have on the reprogramming efficiency and 
fidelity are also still unclear (reviewed in (Vierbuchen and Wernig, 2011)), and associated 
with iN cells’ generation is the question of whether direct reprogramming will or not reset 
the developmental timing, or whether the age of the original cell used for reprogramming 
will impact the age of the obtained target cells (Chambers and Studer, 2011). 
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Finally, understanding how well the reprogrammed cells survive, integrate and 
respond to physiological cues in vivo has a very important role for translational 
applications (Chambers and Studer, 2011). It is important to know how gene expression 
and chromatin structure are shaped by intrinsic mechanisms and by the environment in 
which the cells are, after transplantation. Understanding how a diseased and/or aged 
brain’s environment influences the functionality and gene expression profile of the 
transplanted iN cells, is of extreme relevance for the development of cell-based therapies 
for neurodegenerative disorders. 
 
Within this scenario, future studies will be necessary to determine whether iN cells 
could represent an alternative method to generate patient-specific neurons. The 
differences between the converted cells and their corresponding primary neurons must be 
characterized, and whether they give rise to unwanted side effects should be explored 
(Sendtner, 2011).  
 
The generation of iN cells is fast and devoid of tumorigenic pluripotent cells, a key 
complication of iPSC approaches in regenerative medicine. On top of that, iN cells are 
generated with a higher efficiency, show a relatively rapid conversion and also open the 
possibility for in situ reprogramming (Chambers and Studer, 2011). Therefore, iN cells 
could provide a novel and powerful system for studying cellular identity and plasticity, 
neurological disease modeling, drug discovery and regenerative medicine.  
 
1.3 Lentivirus-mediated gene transfer in the CNS 
 
Most studies on cell fate conversion use lentiviral vectors to deliver reprogramming 
genes. The advantages of using lentiviral vectors as tools in approaches involving gene 
transfer in cultured cells and in the CNS, are well known. LVs are good for these types of 
studies, since they have a great ability to efficiently transduce slowly or non-dividing cells 
(Zufferey et al., 1997) and a large cloning capacity, providing the possibility of carrying 
complex expression cassettes (Naldini et al., 1996a; Wiznerowicz and Trono, 2005). They 
also make it possible to broaden the spectrum of susceptible cells and alter the 
transduction efficiency. This occurs through the pseudotyping of LVs with a variety of 
envelope proteins from different viruses (Watson et al., 2002). For this purpose, the 
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vesicular stomatitis virus (VSV-G) envelope is widely used. Furthermore, LVs integrate 
genes in the chromosome of the target cells, leading to stable long-term expression 
(Azzouz et al., 2002; Blomer et al., 1997; Deglon et al., 2000; Naldini et al., 1996a) and elicit 
minimal inflammatory response that could compromise the viability of the transduced 
cells (Azzouz et al., 2002; Bensadoun et al., 2000; Deglon et al., 2000; Kordower et al., 2000; 
Mazarakis et al., 2001). 
 
Lentiviral vectors can be split into two different groups, the primate, such as the 
ones based on immunodeficiency virus (HIV) (Naldini et al., 1996b) and simian 
immunodeficiency virus (SIV) (Negre et al., 2002), and non primate, such as those derived 
from equine infectious anaemia virus (EIAV) (Mitrophanous et al., 1999)(ref 18_Azzouz) 
and feline immunodeficiency virus (FIV) (Poeschla et al., 1998). 
  
In order to make use of a LV, sequences that act in cis and trans within the genome 
have to be separated. The cis sequences contain signals required for packaging and 
integration of the viral genome as well as the polypurine tract (PPT) and the long terminal 
repeat sequences (LTR). In trans, sequence information coding is stored for proteins that 
compose the virus. Also, trans sequences are provided on more than one vector thus 
minimizing the risk of spontaneous recombination that could lead to replication-
competent vectors. Additionally, a transfer vector containing the transgene of interest 
exists, which represents the lentiviral genome that will be integrated into the host genome 
(Vigna and Naldini, 2000). 
 
Nonetheless the use of LVs in gene therapy approaches for example, HIV-based 
lentivirus-mediated overexpression of TFs for the direct conversion of both human 
embryonic and postnatal fibroblasts into neurons has proved to be successful (Pfisterer et 
al., 2011a). Therefore, a similar approach was used during the project described in the 
present thesis. For the delivery of the TFs into the target cells, the fibroblasts, two different 
types of lentiviral vector constructs (transfer vectors) were used. The first contained an 
internal human phosphoglycerate kinase (hPGK) promoter that drives the transgenes 
expression after integration. Additionally to the promoter sequence, the transfer vector 
contains two cis-acting elements, the central polypurine tract (cPPT) as well as the 
woodchuck hepatitis posttranscriptional regulatory element (WPRE). The latter enhances 
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the transgene expression levels and upgrades the transduction efficiency. The previously 
referred construct was used for carrying ten of the thirteen TFs used in the project 
(described in Figure 5). The second transfer vector, used for the three remaining TF’s 
transgenes, contains a tetracycline-regulated promoter sequence, that drives the 
transcription of the factors upon doxycycline deliver to the cells, the so-called Tet-On 
system. To perform this regulation, an additional vector, encoding for a regulator protein 
(FuW), is necessary. In the presence of doxycycline, that protein binds to a region in the 
inducible promoter, the tetracycline response element (TRE), activating the transcription 
of the transgenes (Graham and Self, 2010). 
 
Alongside the transfer vectors #1000-hPGK and Tet-O carrying the gene of 
interest, the envelope vector pMD2.G, containing the glycoprotein of vesicular stomatitis 
virus (VSV-G) as well as the packaging vectors pMDL/RRE and pRSV-REV, containing 
the sequences rev, pol, gag and tat were also used for LV production. Rev and tat 
sequences encode for proteins regulating viral transcription, while pol encodes proteins 
necessary for the viral life cycle (reverse transcriptase and integrase), and gag encodes 
structural proteins that form the viral capsid (Bour and Strebel, 2000). 
 
 
Figure 5 – Schematic  representation of  the doxycycline-regulated transcription 
system (Tet-On).  
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The upper represented 293T cells are transfected with the transfer vector (Tet-O), pseudotyping 
(pMD.2G) and packaging plasmids (pRSV-REV and pMDL-RRE), while the bottom cells are 
transfected also with pseudotyping and packaging plasmids, but with a different transfer vector 
(FuW), encoding for a regulator protein (TetR). The lentiviruses that are produced by these cells 
are used to co-infect the target cells (fibroblasts). When doxycycline is added to the media in the 
cells, this antibiotic binds to the TetR protein, giving rise to a complex that is able to bind to a 
specific site in the promoter (tetracycline response element (TRE)), allowing transcriptional 
activation of the transgene. 
 
1.4 Hypothesis and Significance of the project 
 
1.4.1 Hypothesis 
The existing information about the ability of the TFs ABM to directly convert 
fibroblasts into functional neurons, and the fact that the addition of fate-specifying factors 
to this cocktail can lead to the generation of a different neuronal subtype (Pfisterer et al., 
2011a), led us to formulate a hypothesis. The combination of those factors with an 
additional cocktail of TFs expressed during striatal development (Dlx2, Dlx5, Isl1, Nolz1, 
Gsx2, Gsx1, Gli1, Otx2, FoxG1 and CTIP2), could lead to the obtention of hiN cells with a 
striatal GABAergic phenotype. The selected TFs have been shown to have a relevant 
significance in brain processes related with striatal and more specifically, striatal 
GABAergic projection neurons’ development (For more detailed information, see Table 
A1). These neurons are by far the most numerous neuronal type in the striatum (80-95%), 
being also known as medium spiny neurons (msn), and are involved in basal ganglia 
pathways, related with the control of movment (Squire, 2008). Since those neurons are 
particularly affected in cases of Huntington’s disease (HD) and stroke, their generation 
through a transdifferentiation process would possibly be a valuable approach to obtain 
cells that could be used in cellular therapy for those diseases. 
1.4.2 Significance of the project 
 In the striatum, there are four main types of neurons described according to the 
size of their cell body and the presence or absence of dendritic spines. These types of 
neurons are: medium spiny neurons (GABAergic), large aspiny neurons 
(Acetylcholinergic), medium spiny cells (Somatostatinergic) and small aspiny cells 
(GABAergic). By far, the most numerous neuron type in the striatum is the medium spiny 
neuron. With large and characteristic dendritic trees and expression of DARPP-32, a 
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dopamine and cAMP-regulated phosphoprotein of 32 kDa (Ouimet et al., 1984), these 
GABAergic projection neurons are neurochemically heterogeneous due to the presence of 
peptide neurotransmitters that are co-localized with GABA. Based on both the type of 
neurotransmitter and the type of dopamine receptor they contain, medium spiny neurons 
can be divided into two populations. One population contains GABA, dynorphin and 
substance P, primarily expressing D1 dopamine receptors, while the other population 
contains GABA and enkephalin and primarily expresses D2 dopamine receptors (Squire, 
2008). The neurons that contain GABA, Dynorphyn and substance P as neurotransmitter 
project from the striatum to the internal segment of globus pallidus and substantia nigra, 
being involved in the direct pathway, while the neurons that contain GABA and 
encephalin project from the striatum to the external segment of globus pallidus and are 
involved in the direct pathway. 
 
These medium spiny neurons receive the bulk of inputs to the striatum, receiving 
afferents from the cortex, thalamus and midbrain, as well as being the major output 
neuron of the striatum, projecting to various regions of the CNS, including the globus 
pallidus and the substantia nigra. As such, they form complex neuronal loops within the 
basal ganglia that are important for the control of movement, cognition and emotion 
(Nakano et al., 2000) (Figure 6). 
      
Figure 6 – Direct  and indirect  pathways in the basal  ganglia  circuitry for the 
control  of  movement.  
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The direct pathway contains two inhibitory GABAergic synapses (between the striatum and the 
internal globus pallidus or substantia nigra, and between the internal globus pallidus or the 
substantia nigra and the thalamus). Activation of this pathway produces desinhibition of the 
excitatory glutamatergic thalamic input to the sensory, motor and associated areas of the cortex. In 
the indirect pathway, there are one excitatory glutamatergic (between the subthalamic nucleus and 
the internal globus pallidus) and three inhibitory GABAergic synapses (between the striatum and 
external globus pallidus, between external globus pallidus and subthalamic nucleus, and between 
the internal globus pallidus and thalamus). In contrast to the direct pathway, the three inhibitory 
synapses result in net inhibition (inhibition of disinhibition) of the thalamic-cortical projections 
when the direct circuit is activated (Siegel et al., 1999).  
 
Huntington’s disease is an autosomal dominant neurodegenerative disorder, 
characterized by an expansion of the CAG polyglutamine repeat of the huntingtin protein. 
It involves the death of projection neurons (medium spiny neurons) in the striatum, 
enlargement of the ventricles and a corresponding shrinkage of the overlying cortex. These 
events of the disease lead to involuntary choreiformic movements, cognitive impairment 
and emotional disturbances (Kelly et al., 2009). Despite identification of the HD gene 
associated proteins, the mechanisms involved pathogenesis of HD remains largely 
unknown, hampering effective therapeutic interventions, and unlike other 
neurodegenerative disorders, like Parkinson’s disease, where several options are available, 
albeit mainly for the early-to-moderate-stage patient, there is little in the way of disease-
modifying treatment available for patients with HD (Kelly et al., 2009).  The mechanisms 
of cell dysfunction and death in HD have been the subject of a number of studies, which 
led to therapeutic strategies largely based on the amelioration of mutant huntingtin-
related metabolic impairment and cellular toxicity. Yet, in later stages of the disease, after 
cell death has become prominent, cell replacement therapy (either by direct cell 
transplantation or by mobilization of endogenous progenitors) may comprise a stronger 
potential avenue for therapy (Benraiss and Goldman, 2011). 
 
Given the predominance of medium spiny neuronal loss in HD, a number of 
investigators have proposed that allogeneic striatal cell grafts, intended to replace lost 
projection neurons, might ameliorate disease progression as well as reducing the neuronal 
damage in HD brain. In fact, an improvement in motor and cognition performance in HD 
patients following fetal cell transplantation was documented (Bachoud-Levi et al., 2000). 
However, as previously referred, the difficulty in supplying sufficient amounts of 
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embryonic striatal tissue and the concomitant ethical issues associated with the use of 
human embryonic tissue made the use of these cells for transplantation more difficult. 
 
Several donor tissues alternatives are now being actively explored. First, there is the 
potential to take into culture the primary tissue and NSC, either with a view to expanding 
the number of progenitors with the potential to differentiate into medium spiny neurons, 
thus avoiding the need for multiple fetal donors per patient, or by using them as a source 
for transplantation, after which they could develop and differentiate into regionally 
appropriate cell types in response to environmental factors (Flax et al., 1998; Gage, 2000; 
Gottlieb, 2002; Kelly et al., 2009; Kim, 2004; Lindvall and Kokaia, 2006; Temple, 2001). 
Other cell types were also used in animal models, such as ESCs, MSCs, primary human 
NPCs, and resulted in varying degree of clinical improvement (Armstrong et al., 2000; 
Kordower et al., 1997; Lee et al., 2005; Lee et al., 2006; McBride et al., 2004; Ryu et al., 
2004; Visnyei et al., 2006).  
 
A variety of disease-specific iPSCs, including those for HD, have been generated 
and have already found uses in drug screening and in the investigation of disease-specific 
molecular pathways (Beyene and Boockvar, 2008; Ebert and Svendsen, 2010; Park et al., 
2008; Zhang et al., 2010). These cells also comprise an important source of cells for 
phenotype-specific cell replacement and tissue repair. However, since the risks of 
transplanting iPSC-derived cells are still under evaluation, an alternative source for 
generation of neurons would be necessary.  
 
Since HD is a genetic disorder, and given the underlying CAG repeat expansions of 
the donor cells, when using patient-specific cells, further genetic modification in the donor 
cells would be needed before transplant. Several techniques have already been developed 
to achieve this end, all directed to the inactivation or blockade of mutant huntingtin gene 
expression (Benraiss and Goldman, 2011). Future studies involving iN cells for cell 
replacement therapies in HD would have to address this issue, by removing or inactivating 
the offending segment of poly-CAG expansion. 
 
The stroke, medically known as cerebrovascular accident (CVA), is caused by 
blockage of a cerebral artery, leading to focal ischemia, loss of neurons (the most sensitive, 
like medium spiny neurons) and glial cells, and motor, sensory and cognitive 
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impairments. No effective treatment to promote recovery exists, so a therapy that 
produced even minor improvement would be valuable (Lindvall and Kokaia, 2006). Thus, 
the role of cellular therapy as an approach to repair has been explored. 
 
The concept of restoring function after stroke by transplanting human neuronal 
cells into the brain was conceived in the mid-1990’s (Bonn, 1998), and a variety of cell 
types have been tried for restoration of brain function after stroke, mostly in rodent 
models: fetal tissue, rat striatum, LBS neurons, NT2-teratocarcinoma-derived cells, ESC-
derived neurons and marrow stromal cells (Borlongan et al., 1995; Borlongan et al., 1997; 
Borlongan et al., 1998a; Borlongan et al., 1998b; Chen et al., 2001a; Chen et al., 2001b; 
Hayashi et al., 2006; Ikeda et al., 2005; Li et al., 2002; Li et al., 2001; Li and Chopp, 2009; Li 
et al., 2000; Nishino et al., 1993; Saporta et al., 1999). These attempts to promote recovery 
of the affected subjects were in some cases successful, leading to restoration of cognitive 
and motor functions. A clinical trial was reported, in which stroke patients, with affected 
basal ganglia, received implants of neurons generated from the human NT-2 
teratocarcinoma cell line into the infarcted area (Kondziolka et al., 2000; Meltzer et al., 
2001). Some improvement was observed in some patients, but those were correlated with 
increased metabolic activity at the graft site (Meltzer et al., 2001). 
The generation of neurons from a somatic source, like fibroblasts for example, 
could help find a solution for using in cell-based therapies for HD and stroke. Therefore, 
the use of iN cells with characteristics that could resemble the striatal GABAergic 
projection neurons’ phenotype, expressing the same markers and with the same functional 
properties seems very appellative.  
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2.1 Cell  cultures maintenance, expansion and sub-culture 
2.1.1 293T cells 
 293T cells were grown in DMEM+GlutaMAXTM-I (Dulbecco’s Modified Eagle 
Medium with 4,5 g/L of Glucose; Gibco, Invitrogen), supplemented with 10% of standard 
Fetal Bovine Serum (Saveen & Werner) and 1% of Penicillin/Streptomycin (Gibco, 
Invitrogen), and maintained at 37°C in humidified atmosphere with 5% CO2 in air (Forma 
Scientific incubator).  
2.1.2 Human embryonic fibroblasts   
 Cultures of human embryonic fibroblasts (hEFs) were derived from legally aborted 
fetuses aged 5.5-7 weeks postconception with approval of the Swedish National Board of 
Health and Welfare and the Lund/Malmö Ethics committee. After neural tissue removal as 
well as removal of all red organ, hEFs were expanded in culture. Direct conversion 
experiments were performed on hEFs either in passage 3 or 4. Before plating the cells, all 
flasks and plates were coated with 0,1% Gelatin (Sigma Aldrich) (45 minutes, 37°C). The 
hEFs were grown in MEF medium, composed by: DMEM+ GlutaMAXTM-I supplemented 
with 10% FBS (Gibco, Invitrogen), 1% 10 000 µg/mL Pen/Strep (Gibco, Invitrogen) and 
1% 200mM Glutamine (Sigma Aldrich). All components were filtered (sterile filter; 0,2µm 
pores; Nunc, Thermo Scientific). The cells were kept at 37°C in humidified atmosphere 
with 5% CO2 in air (Thermo Forma Steri-cycle CO2 incubator).  
2.1.3 NSE14 cells 
In 2005, Conti et al. demonstrated that the combination of epidermal growth 
factor (EGF) and fibroblast growth factor 2 (FGF2) is sufficient for derivation and 
continuous expansion of pure monolayer cultures of mouse embryonic stem cell-derived 
neural stem cells (ES cell derived NS cells)(Conti et al., 2005). Conti and colleagues 
established the ES cell-derived NS cell line NS. Before plating the cells, all the flasks and 
plates were coated with 0,1% Gelatin (45 minutes, 37°C). The NSE14 cells were kept in 
culture and grown in Euromed-N medium (Optimized medium for neuronal precursor 
cells, EuroClone) supplemented with 1% 200mM L-Glutamine (Sigma Aldrich), 1% 10 000 
µg/mL Pen Strep (Gibco, Life TechnologiesTM) and 10x Hormone mix (prepared with 1 
mg/mL Apo-transferrin, 250µg/mL Insulin, 96,6 µg/mL Putrescine, 51,8 ng/mL Sodium 
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Selenite and 62,9 ng/mL Progesterone (Sigma Aldrich) in Euromed-N medium). The 
medium was prepared by filtering all the components (sterile filter; 0,2µm pores; Nunc, 
Thermo Scientific). Before adding the medium to the cells, it was also supplemented with 
Growth factors: 0,1% 20µg/mL bFGF (Gibco, Life TechnologiesTM) and 0,02% 100µg/mL 
EGF (R&D systems). The cells were maintained at 37°C in humidified atmosphere with 
5% CO2 in air (Thermo Scientific incubator).  
2.1.4 Cells expansion and subculture  
The medium in all the cell lines was changed every 2-3 days. The cells were split 
depending on their cell density and special care was taken to avoid cell densities above 
75%. For cell splitting, the cell monolayer was washed with sterile DPBS 1X (Dulbecco’s 
Phosphate Buffered Saline; Gibco®, Invitrogen) and then dissociated using Trypsin 1X 
(Gibco®, Invitrogen) (3-5 minutes, 37°C) or Accutase solution 1x (in the case of NSE14 
cells; PAA laboratories GmbH) (3 minutes, 37°C).  After pelletizing the cells (5 minutes, 
400 x g or 1200 rpm, 20°C) (Rotina 35R Centrifuge, Hettich; Biofuge primo R, Heraeus) 
and removal of the supernatant, the cell pellet was resuspended in culture medium. The 
cell number was determined manually by using a Bürker chamber (Marienfeld) by 
counting the cell number within a minimum of three fields and cells were plated at the 
desired cell numbers into new T25 or T75 flasks (Nunc, Thermo Scientific).  
 
2.2 Lentiviral  production 
Production of lentiviruses was performed in the variant of human embryonic kidney 
(HEK) 293 cells containing the SV40 largeT-antigen (293T cells). For viral production, 3rd 
generation lentiviral packaging and envelope plasmids were used. One day prior to 
transfection, 293T cells were plated in T175 flasks at a density of 10x106 cells per flask. For 
the production of one virus batch, the supernatant of 2 flasks was pooled. 
One day after plating and 2-3 hours prior to transfection, the medium in the cells 
was changed to IMDM+GlutaMAXTM-I (Iscove’s Modified Dulbecco Medium, 25 mM 
HEPES, Gibco, Invitrogen) supplemented with 10% of FBS and 1% of Pen/Strep.  
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Table II  –  Plasmids used for transfection and their  correspondent necessary mass 
for the production of  each batch of  lentiviral  particles .  
Plasmids used for transfection 
Mass/batch 
(µg) 
Envelope 
plasmid 
pMD2.G 21,1 µg 
Packaging 
plasmids 
pMDL/RRE 29,3 µg 
pRSV-REV 14,6µg 
Transfer vector 
(*1) 
   Ascl1, Myt1L, Brn2, Dlx2, Dlx5, 
Isl1, Nolz1, Gsx1, Gsx2, Gli1, Otx2, 
FoxG1, CTIP2 and FuW (*2) 
75µg 
 
 (*1) Each one of the vectors containing the different transcription factor’s sequences is transfected 
in 293T cells independently. 
 (*2)   FuW is the transactivator that allows the transcription of Ascl1, Myt1L and Brn2, whose 
expression is driven by a Tetracycline-regulated promoter. The remaining factors are transcribed 
under an ubiquitous and constitutively active promoter (hPGK). 
 
The packaging, envelope and transfer vectors were added to 2500µL of TE-buffer 
0,1% (TE-buffer 1X diluted 1:10 with distilled water; TE-buffer 1X: 10mL of 1M Tris-HCl 
pH 7.5, 2 mL of 0,5M EDTA pH 8.0 and 988 mL ddH2O) at the desired concentrations 
listed above (Table II) Subsequently, CaCl2 was added to the solution (292,5 µL) and left 
for 5 minutes at room temperature. After incubation, 2800µL of HeBS 2X (Hepes-buffered 
solution; 8,0 g NaCl, 6,5 g HEPES in 10 ml NA2HPO4 (5,25 g sodium phosphate dibasic in 
500 mL distilled water), filled up to 500 mL with distilled water; pH 7,0) was added 
dropwise to the DNA/CaCl2 solution, under vortex mixing (Vortex Genie, Scientific 
Industries, Labora). The final solution was then pipetted on cells carefully (2800 µL/T175 
flask). The cells were maintained in the incubator at 37°C in a 5% CO2 in air atmosphere.  
 
 All the procedures involving viruses handling were performed by trained 
personnel and according to p2 laboratory safety guidelines. Before discarding pipet tips, 
they were incubated in Virkon®, a strong antiviral agent and after usage, the bench, all the 
material and equipment used during the procedures were exposed to UV light for 20 
minutes. 
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The culture medium was changed 12-14 hours after transfection. Approximately 
30 hours post medium change, the medium of each batch was collected and centrifuged 
(800 x g, 10 minutes, 20° C). After filtering (0,45µm pore filter, Nunc), the supernatant 
was subsequently subjected to ultracentrifugation (Beckman Optima L-60 ultracentrifuge) 
(19500 rpm, 2 hours, 4°C).  The supernatant was discarded diligently to avoid any 
contamination by remainder of medium. The pellet was then resuspended with 90µL of 
PBS (2 hours at 4°C) and aliquots of the viruses were stored at -80°C. 
 
2.3 RNA studies 
2.3.1 RNA extraction 
Cells were plated in 6-well plates (2,0 x 105 cells/well) and infected with the different 
lentiviruses at desired multiplicity of infection (MOI = number of viral particles/ number 
of target cells). At various timepoints, cells were directly harvested in 350µL RLT lysis 
buffer (QIAgen) and RNA Extraction was performed using the RNeasy® Microkit 
(QIAgen) following main manufacturer’s instructions (RNeasy Micro Handbook, 12/2007, 
pages 16-22). 
The RNA concentration and grade of purity (Ratio OD260nm/280nm range 1.8-2.2) in the 
final samples was determined by using the Nanodrop 2000 (Thermo Scientific), and 
represented in ng/µL. 
2.3.2 Reverse transcription and cDNA synthesis 
Equal amounts of extracted RNA (range: 300-500 ng) were incubated at 65°C for 5 
minutes in S1000 TM Thermal Cycler (Bio-Rad) after being mixed with dNTP (10 mM each 
dATP, dGTP, dCTP and dTTP at neutral pH) and random-primers mix (Fermentas), 
according to suplier’s recommendations, added to a final volume of 13 µL with distilled 
water. After the incubation, 0,1 M DTT, First-Strand Buffer (5x) and Super Script® III 
Reverse Transcriptase (Invitrogen) were added to the samples. For each sample, a negative 
control was prepared, by adding the previously described reaction mix without the enzyme 
(referred to as –RT control). In both conditions, the final volume per sample was 20µL. 
Before performing the reaction, the samples were incubated in ice for 5 minutes. Reverse 
transcription was performed at 50°C for 1 hour for primer annealing and cDNA synthesis, 
                                 Direct conversion of human fibroblasts into striatal neurons by defined factors 
 35 
followed by 70°C for 15 minutes, in order to denature the reverse transcriptase. The 
sample was cooled to 4°C, diluted 1:5 in distilled water and stored at -20°C until further 
use. 
2.3.3 Primers design and preparation 
The primers designed for real time quantitative PCR (qRT-PCR) were used for 
detection of the target DNA of the ten transcription factors after lentiviral overexpression 
as well as for detection of the reference genes β-Actin and GAPDH.   
All the primers used for qPCR analysis were designed using the open source 
software tool Primer3 (v0.4.0). Primer pairs were designed complementary to the cDNA 
sequence of the individual detection targets. The primers were selected according to the 
following criteria: a) GC content about 50%; b) Melting temperature (Tm) of 
approximately 60°C; c) Primer length of 18-23 bp; d) Final product length of 70-150 bp; 
and e) Secondary structures and primer-dimers were avoided. 
A first pair of primers was designed for each transgene in order to recognize a 
nucleotide sequence containing part of both the WPRE sequence (lentiviral) and transgene 
sequence (primers type A, figure 7), allowing the discrimination between the endogenous 
and virally mediated gene expression. 
A second pair of primers was designed for Dlx2, Dlx5 as well as CTIP2, in order to 
recognize each individual transgene’s open reading frame (ORF) (primers type B, figure 
7). The primer pairs designed in the second set do not distinguish endogenous from 
exogenous gene expression, but enable for detection of an increase in gene expression in a 
dose-dependent fashion. 
 
Figure 7 -  Schematic  representation of  the sites  of  hybridization of  the primers 
designed in both sets  (A and B). 	  	  
The expression of the transgenes is driven by the human phosphoglycerate kinase (hPGK) 
promoter. Primers type A (fw and rv) are amplifying a region spanned between the transgene 
sequence and WPRE sequence. Primers type B (fw and rv) recognize the ORF of each transgene. 
 
B fw B rv A fw A rv 
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 The primers were ordered (Sigma-Aldrich) desalted, at standard concentrations, 
diluted (0,95µM) and stored at -20°C until further use. 
In table III and IV, a list of the primers and the respective sequences are presented. 
 
Table III  –  Forward and reverse sequences of  the pairs  of  primers designed for 
qPCR analysis .   
The primers shown here recognize both the WPRE sequence (rev primer) and part of the 
transgene sequence (fw primer). 
Transgene Forward Primer Sequence Reverse Primer Sequence 
Otx2    
(mouse) 
5’-GATCAGACGTCCTCATGGAAA-3’ 5’-­‐CCACATAGCGTAAAAGGAGCA-­‐3’ 
Gli1     
(mouse) 
5’-­‐GCCTGGAGAGACACAATTCC-­‐3’ 5’-­‐CCACATAGCGTAAAAGGAGCA-­‐3’ 
CTIP2 
(human) 
5’-­‐AGGCCGAGAGGAGCTAAGTC-­‐3’ 5’-­‐CCACATAGCGTAAAAGGAGCA-­‐3’ 
Dlx2    
(human) 
5’-­‐GCGGGGACGATTTTCTAAGT-­‐3’	   5’-­‐CCACATAGCGTAAAAGGAGCA-­‐3’ 
Dlx5    
(human) 
5’-­‐GCCTCCGGGACACTCTATTA-­‐3’ 5’-­‐AGCGTAAAAGGAGCAACATAGT-­‐3’ 
FoxG1 
(human) 
5’-­‐GGGTCTTCTTCCAACCCTTT-­‐3’ 5’-­‐CCACATAGCGTAAAAGGAGCA-­‐3’ 
Gsx1    
(human) 
5’-­‐AAGGACGACCGGGATCTTAC-­‐3’ 5’-­‐GGCATTAAAGCAGCGTATCC-­‐3’ 
Gsx2    
(human) 
5’-­‐GCCAACGATGACAAGGAGAT-­‐3’	   5’-­‐CCACATAGCGTAAAAGGAGCA-­‐3’	  
Isl1      
(human) 
5’-­‐AACAGCATGGTAGCCAGTCC-­‐3’	   5’-­‐GGCATTAAAGCAGCGTATCC-­‐3’	  
Nolz1  
(mouse) 
5’-­‐CCTTATGCCCTCTACGGACA-­‐3’	   5’-­‐CCACATAGCGTAAAAGGAGCA-­‐3’	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Table IV – Forward and reverse sequences of  the pairs  of  primers designed for 
qPCR analysis  (second set) .   
The primers presented here are primers that are able to hybridize centrally with the DNA sequence 
of the open reading frame (ORF) of the transgenes. 
Transgene Forward Primer Sequence Reverse Primer Sequence 
CTIP2 
(human) 
5’-CCATCCTCGAAGAAGACGAG-3’ 5’-ATTTGACACTGGCCACAGGT-3’ 
5’-TCCAGAGCAATCTCATCGTG-3’ 5’-GTGCATGTGCGTCTTCATGT-3’ 
5’-GGCAAGACCTTCAAGTTCCA-3’ 5’-GTGCATGTGCGTCTTCATGT-3’ 
5’-TCCAGAGCAATCTCATCGTG-3’ 5’-TGCATGTGCGTCTTCATGT-3’ 
Dlx2    
(human) 
5’-AGCAGCTATGACCTGGGCTA-3’ 5’-TCCTTCTCAGGCTCGTTGTT-3’ 
Dlx5    
(human) 
5’-TGAGAATGGTGAATGGCAAA-3’ 5’-GCAAGGCGAGGTACTGAGTC-3’ 
 
2.3.4 Real time RT-PCR (qRT-PCR) 
For gene expression analysis, qRT-PCR was carried out using the non-specific dye 
SYBR Green. The reaction was performed using a SYBR Light Cycler® 480 (Roche) 
according to standard procedures. The samples (including negative controls), SYBR Green 
mastermix (Roche) and individual primers (0,95µM) were pipetted in triplicates by using 
the VarispanArm (Perkin Elmer) robot, into 384-well plates. Data analysis was made 
according to the second derivative method (Abs Quant/2nd Derivative Max). 
 
2.4 Lentiviruses titration and Validation of the constructs 
2.4.1 Lentiviruses titration 
For lentiviruses titration, and after the procedures described in 2.2, the viruses were 
used to infect 293T cells, which were plated on 6-well plates in a density of 1,0 x 105 cells 
per well, as described in 2.1. The 293T cells were infected with three different 
concentrations (3, 1 and 0,3 µL) of each virus, as well as a virus containing a reference 
gene, individually. The titer of the reference gene has been determined beforehand via 
FACS analysis for GFP. After DNA extraction (DNeasy® Blood and Tissue Kit, Qiagen), 
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performed three days after infection and according to the main manufacturer’s 
instructions (Blood and Tissue Handbook, 07/2006, pages 25-27), real time PCR (qPCR) 
was carried out, as described in 2.3.4, using Taqman® primer probes specific for WPRE 
and Albumin genes, in order to determine the lentiviruses titers (U/mL). 
2.4.2 Validation of the constructs 
In order to validate the constructs containing the transcription factors’ sequences, after 
the procedures described in 2.2, 293T and NSE14 cells were plated in 6-well plates as 
described in 2.1, in a density of 2,0 x 105 cells per well, and infected with three different 
increasing concentrations of each virus (1, 3 and 5µL).  Three days after transduction, total 
RNA was extracted and cDNA synthesized (according to 2.3.1 and 2.3.2, respectively). 
qRT-PCR was performed (see 2.3.4) in order to detect an increase in transgene expression 
in a dose-dependent fashion, according to the different concentrations of viruses used for 
transduction.  
 
2.5 In vitro  differentiation studies 
2.5.1 Screening approach 
In 2011, Kim, J. et al. utilized a screening approach involving direct conversion of 
mouse fibroblasts to induced neurons (iN), to determine a crucial set of transcription 
factors sufficient to induce a dopaminergic fate in iN cells. The eleven initial TFs were 
divided in three different groups depending on biological function and expression 
patterns. Subsequently, the ability of each group of TFs to generate dopaminergic iN cells 
was tested by using a subtractive approach (Kim et al., 2011). 
To investigate the in vitro differentiation process of human fibroblasts into striatal 
GABAergic projection neurons and the contribution of the TFs selected to perform the 
screening, thirteen TFs were organized in four different groups according to their 
biological functions and patterns of expression (see table A1, Appendix, detailed 
classification in categories of all individual TFs). 
In group 1 were the conversion factors, Ascl1, Myt1L and Brn2, known by their 
capacity to convert fibroblasts into neurons (Vierbuchen et al., 2010). In Group 2, the 
TFs CTIP2, Isl1 and Nolz1 were grouped, which are involved in the striatal  medium 
spiny neurons’ development specifically, while in Group 3, Dlx2, Dlx5 and Gsx2, 
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TFs that seemed to be related to the striatal  development. Finally, in group 4, the 
TFs Gli1, Otx2, FoxG1 and Gsx1 that were grouped together since they are considered as 
specific and related to early CNS development.  
One day prior to transduction, hEF cells at passage numbers of either 2 or 3 were 
plated in 24-well plates, at a density of 2,0 x 104 cells per well, according to the procedures 
described in 2.1.  
2.5.2 Transcription factors’  combination and infection 
Solutions containing the individual viruses were prepared in MEF medium at a 
multiplicity of infection (MOI=number of lentiviral particles/number of target cells) of 4 
for all the striatal and conversion factors, and an MOI of 8 for the transactivator lentivirus 
(FuW) (exceed of transactivator ensuring dox-mediated transgene expression). In the 
course of transduction, the entire medium per well was replaced by the previously 
described viral solution.  
We designed a strategy in order to address the importance of the groups for the 
conversion of the hEFs. First, each one of the groups of factors, as well as a combination of 
all the groups of factors together were used to infect the hEFs. On top of that, all possible 
combinations of three groups per condition were tested. For each one of the conditions, 
three technical replicates (three wells per condition) were made, and 15 days after 
transgene activation, converted cells were quantified by using Immunocytochemistry. 
For more detailed information about the grouping of the different TFs into the four 
groups, and the functions and patterns of expression of each TF individually, see table A1, 
Appendix. 
2.5.3 Differentiation protocol 
Post infection, the cells were cultured in MEF medium for 6 days and the medium was 
changed every 2-3 days, according to standard cell culture procedures (described in 2.1). 
Doxycycline (2 µg/mL) was added to the cells six days after transduction, and two days 
after this, the medium was changed to N2B27 (Neural differentiation medium, Stem Cells) 
supplemented with 1% PenStrep, and also supplemented with doxycycline (2 µg/mL) and 
neurotrophic factors (Ascorbic Acid (AA) 0,2 mM, GDNF 0,01 µg/mL, BDNF 0,02 µg/mL 
and Retinoic Acid (RA) 100 nM). Every 2nd to 3rd day, ¾ of the medium in the wells was 
changed until termination of the experiment. The protocol of differentiation lasted 15 
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days (after doxycycline was added) and the cells were then fixed with PFA 4% (Sigma 
Aldrich). The following figure shows a timeline for the in vitro differentiation studies. 
 
Figure 8 -  Timeline for the differentiation protocol.   
One day prior to infection, hEFs were plated at a density of 2,0 x 104. The infection was then made 
in the next day and the cells were kept in culture for 6 days, during which the medium was 
changed every 2-3 days. Doxycycline was added (Day 1) and 2 days after, all medium was changed 
to N2B27, supplemented with Doxycycline and neurotrophic factors (ascorbic acid, GDNF, BDNF 
and retinoic acid). ¾ of the medium were changed every 2-3 days until the end of the 
differentiation protocol (Day 15), when the cells were fixed with PFA 4%.   
 
2.5.4 Comparison of differentiation protocols 
The abovementioned differentiation protocol was selected based on previous 
experiments made in the lab that showed that delaying the doxycycline addition to the 
cells for six days yielded higher number of converted cells (unpublished data) than adding 
doxycycline one day after transduction (Pang et al., 2011; Pfisterer et al., 2011a; 
Vierbuchen et al., 2010).  
In April 2012, Ladewig and colleagues showed that by using a combination of SM 
involved in the inhibition of the SMAD pathway and of the GSK-3β (SB-431542 together 
with noggin and CHIR99021), with a minimum number of TFs (Ascl1 and Neurogenin 2 
(Ngn2) (AN)) it is possible to achieve a highly efficient neuronal conversion of human 
fibroblasts (Ladewig et al., 2012).  
 
We set out to explore the potential of different differentiation protocols to generate 
hiN cells. In order to do so, we applied the conversion factors Ascl1, Brn2 and Myt1L 
(group 1) to hEF cells in five different settings of direct conversions as listed below:  
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Condition I – dual SMAD inhibition (according to (Ladewig et al., 2012)); 
Condition II – delayed doxycycline protocol (described above); 
Condition III – dual SMAD inhibition with delayed doxycycline and using the 
neurotrophic factors suggested by Ladewig et al.; 
Condition IV – No doxycycline delay (Pfisterer et al., 2011a); 
Condition V - dual SMAD inhibition with delayed doxycycline and using the 
neurotrophic factors as described above (2.5.3). 
 
In order to compare the new conversion protocols with the previously used and to 
evaluate maturation of generated hiN cells, two different timepoints were selected to fix 
the cells with 4%PFA (days 15 and 28). The combination of the conversion factors Ascl1 
with Ngn2 was also tested in the same different conditions. Further analysis was 
performed by Immunocytochemistry.  
  
SM were tested using the following final concentrations: 10 µM SB, 500 ng/mL 
Noggin (R&D systems) and 2 µM CHIR (Axon). For conditions I and III, a different 
cocktail of neurotrophic factors was used: BDNF (10 ng/mL), GDNF (2 ng/mL), 
Neurotrophin 3 (NT3; 10 ng/mL) (R&D systems) and dcAMP (0,5 mM) (Sigma Aldrich).  
 
2.6 Characterization of the reprogrammed cells  
2.6.1 Immunocytochemistry 
Immunofluorescence stainings were performed on the fixed cells, starting with a 1 
hour incubation with blocking solution, 5% normal donkey serum in 0,025% TKPBS (12,5 
mL 10% Triton in 487,5 mL of KPBS; Sigma Aldrich), followed by an over-night 
incubation at 4°C with a solution containing the primary antibodies, which were diluted 
in blocking solution (5%) (Table V). Cells were then rinsed three times with TKPBS and 
after that, incubated again for 1 hour with blocking solution (5%).  A dilution of secondary 
antibodies was then made in blocking solution (5%) (Table VI) and used in a 2 hours’ 
incubation at room temperature, in the absence of light. Finally, the cells are rinsed three 
times in TKPBS and kept in this solution until they were used for fluorescence 
microscopy. 
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Table V – Primary Antibodies used in the immunocytochemistry assays.   
Primary 
antibodies Host Dilution 
βIII-tubuliin 
(Promega) Mouse 1:1000 
GABA 
(Sigma) Rabbit 1:1000 
DARPP-32 
(Epitomics) Rabbit 1:250 
Isl1 
(Hybridoma bank) Mouse 1:100 
 
Table VI – Secondary antibodies used in the immunocytochemistry assays.  
Secondary antibodies Company Dilution 
Cy2 donkey-α-mouse 
Jackson ImmunoResearch 
laboratories, Inc. 
1:200 Cy3 donkey-α-rabbit 
Cy5 donkey-α-rabbit 
DAPI 1:1000 
 
2.7 Quantifications 
 
In order to quantify the reprogrammed cells, 30-36 representative pictures were taken 
per well (condition) (Leica DFC360 FX + DMI 6000B). To calculate the average 
percentage of converted cells, DAPI+/βIII-tubulin+ double positive cells were counted in 10 
pictures from each condition, and the percentage of converted cells calculated for each 
picture, relating the number of DAPI+/βIII-tubulin+ double positive cells to the total 
number of DAPI-positive cells. The average of the obtained percentages was then 
calculated, as well as the SD (standard deviation). In some conditions, with a very low 
number of converted cells, the number of taken pictures was lower, including only fields, 
which contained converted cells. 
For the calculation of the number of neurons per mm2, the total number of 
DAPI+/βIII-tubulin+ double positive cells in 36 pictures was counted, and by relating to the 
surface area of each field, the total number of neurons per well was calculated, and thus 
                                 Direct conversion of human fibroblasts into striatal neurons by defined factors 
 43 
the number of neurons/mm2 determined. In some cases, the exact number of βIII-tubulin+ 
was determined, since there was a very low number of converted cells, and therefore there 
was no need to extrapolate a total value (the screening was performed through the analysis 
of the entire well) 
The conversion efficiency was determined according to previously described analysis 
methods (Vierbuchen et al., 2010), in which the total number of converted cells id divided 
by the number of plated cells, and the result presented as a percentage.  
Exact numbers of GABA-expressing cells were quantified by manually screening each 
individual well, with no use of any kind of extrapolation. 
The percentage of GABAergic hiN cells was determined relatively to the total number 
of converted cells, per condition. 
In the course of the last experiment (described in 2.5.4), the Cellomics array scan 
(Array Scan VTI, Thermo Fischer) was used. This array allows for unbiased high content 
analysis, quantifying the cells based on the presence of marker expression. As a first step, 
cells were identified as cell counts, based on the size of the nucleus and expression of the 
nuclear marker DAPI. Subsequently, intensity levels in different fluorescent channels 
representing different biological markers were determined based on a set of representative 
test fields, taken manually by the operator. Then, events were defined based on the 
combination of marker expression in the beforehand selected channels (DAPI+/MAP2+ or 
DAPI+/MAP2+/GABA+, for example). The cellomics array scan screened the wells by 
taking 30 random pictures, in a spiral fashion, from center to outside. All images were 
acquired by using a 10x magnification objective. The obtained data is represented as total 
number of cell counts, positive for the defined events, thus allowing for representing the 
data as percentage of converted cells as well (MAP2+/DAPI+). 
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3.1 Validation of the LentiStria vectors by qRT-PCR 
3.1.1 Validation of seven of the LentiStria vectors by qRT-PCR, in 293T 
cells 
This lab has successfully used lentivirus-mediated overexpression of TFs for the 
direct conversion of both human embryonic and postnatal fibroblasts into neurons 
(Pfisterer et al., 2011a). Lentiviruses are good tools for these types of studies, since they 
have a great ability to efficiently transduce slowly or non-dividing cells (Zufferey et al., 
1997) and a large cloning capacity, providing the possibility of carrying complex 
expression cassettes (Naldini et al., 1996a; Wiznerowicz and Trono, 2005). They also make 
it possible to broaden the spectrum of susceptible cells and alter the transduction 
efficiency, allowing for stable and long-term gene delivery. 
The ORF coding sequences of ten TFs were cloned into LV#1000-hPGK (Figure 
A2, Appendix), and these constructs were used to produce the lentiviral vectors 
(lentiStria), that were subsequently used for infection of human embryonic fibroblasts 
(hEFs). 
In order to test the biological functionality and correctness of the lentiStria 
constructs, these were validated on 293T cells. For this purpose, we assessed their ability to 
produce a dose-dependent increase in the expression of the TFs assayed by qRT-PCR. The 
produced lentiviruses, carrying the transgene of interest, were used to infect 293T cells at 
three different increasing concentrations (1, 3 and 5 µL), individually, followed by gene 
expression analysis.  
During the first attempt to validate the constructs, we used primers that were able 
to amplify a fragment spanned between the transgene and WPRE (viral) sequences. This 
kind of primer allows distinguishing between transgenes that are virally delivered or 
endogenously expressed. qRT-PCR using these primers demonstrated that seven of the ten 
transcription factors (FoxG1, Gli1, Gsx1, Gsx2, Otx2, Isl1 and Nolz1) yielded a dose-
dependent increase in transgene expression, when transduced in 293T cells (Figure 9). No 
expression was detected in untransduced 293T cells. A second qRT-PCR round was 
performed, which allowed confirming the previous observations.   
 In the case of the three remaining constructs, no dose-dependent increase in the 
expression of the TFs Dlx2, Dlx5 and CTIP2 was observed. Additionally, some expression 
of Dlx2 and Dlx5 was observed in the untransduced 293T cells. 
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Since it was not possible to observe an increase in the expression of those factors 
(Dlx2, Dlx5 and CTIP2), a different type of primers was designed. These primers 
hybridized exclusively within the coding sequence and did not recognize any viral 
sequences. Even not distinguishing between virally delivered and endogenously expressed 
transgenes, these primers would be able to detect a dose-dependent increase in the 
expression of the TFs, specially in relation to the uninfected control cells. In this attempt 
to validate the three constructs, it was still not possible to detect a dose-dependent increase 
in the expression of CTIP2 by using these primers. Expression of CTIP2, Dlx2 and Dlx5 
was detected by qRT-PCR in the control (untransduced) 293T cells, indicating that these 
cells probably were not suitable for the validation of these three constructs. 
 
 
 
Figure 9 -  Validation of  seven LentiStria  vectors by qRT-PCR, in 293T cel ls .   
The graphs show the dose-dependent increase in the expression of the transcription factors in 
293T, normalized to the control (untransduced) and in relation to the housekeeping genes 
GAPDH and β-Actin. The vectors carrying the TFs’ transgenes FoxG1, Gli1, Gsx1, Gsx2, Otx2, Isl1 
                                 Direct conversion of human fibroblasts into striatal neurons by defined factors 
 49 
and Nolz1 were validated through qRT-PCR, using primers that could detect both part of the 
transgene sequence and the viral sequence WPRE. 
 
3.1.2 Validation of two of the three remaining lentiStria vectors by qRT-
PCR, in NSE14 cells 
After validating seven of the lentiStria constructs using 293T cells, three of them 
remained to validate.  Since there was detection of Dlx2 and Dlx5 expression in the 
untransduced human 293T cells, we then proceeded to overexpress these two TFs in a 
mouse cell line that do not express them, the NSE14. It was possible to observe a dose-
dependent increase in the expression of Dlx2 and Dlx5, with no expression in the 
untransduced NSE14 cells. These observations confirmed that the two constructs 
effectively allow the TFs’ overexpression in the transduced cells, as well as a dose-
dependent increase in their expression (Figure 10). By doing so, they were considered as 
validated in NSE14 cells.  
 
 
 
Figure 10 – Validation of  the constructs  containing the Dlx2 and Dlx5 transgenes 
by qRT-PCR, in NSE14 cel ls .   
The graphs show a dose-dependent increase in the expression of the transcription factors in NSE14 
cells, normalized to the control (untransduced) and in relation to the housekeeping genes GAPDH 
and β-Actin. The vectors were validated by qRT-PCR, using primers that could detect only the 
transgene sequence of the transcription factors. 
 
3.1.3 qRT-PCR studies did not allow for the validation of the LV#1000-
CTIP2 construct 
In an attempt to validate the CTIP2 transgene-carrying construct, NSE14 cells were 
also used. Three different additional primer pairs were designed for this validation 
(described in table IV, 2.3.3).  
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A high background expression on the untransduced NSE14 cells was detected and 
again, no dose-dependent increase in the expression was verified. We then proceeded to 
verify the correctness of the cloned construct, by digesting it with three different 
restriction enzymes (BamH1, SalI and MluI) and then comparing the resulting bands with 
the expected restriction digest pattern. According to this, it was possible to observe the 
expected pattern of bands in the different digestions (Figure A3, Appendix). Thus, it 
seems that the CTIP2 construct’s sequence is correct. The validation of this construct 
remains to be completed and will be addressed in future experiments. 
 
3.2 Direct conversion of hEFs into hiN cells  
3.2.1 Experimental design 
To investigate the in vitro conversion process of the hEFs and the contribution of 
the TFs selected to perform this screening, thirteen TFs were organized in four different 
groups according to their functions and patterns of expression (see table A1, Appendix) 
where these aspects are summarized for each TF individually).  
We then designed a strategy in order to address the importance of the groups for 
the conversion of the hEFs. This contribution was determined by infecting the hEFs with 
different combinations of lentiviruses containing the TFs’ transgenes. First, each one of 
the groups of factors was used to infect the hEFs individually (Figure 11, A) as well as a 
combination in which all the groups of TFs were included (Figure 11, B) and then, 
different combinations of three groups per condition, in which one of the groups was 
lacking in the pool, were tested individually (Figure 11, C). For each one of the conditions, 
3 technical replicates (3 wells per condition) were made, and 15 days after transgene 
activation, converted cells were quantified by using Immunocytochemistry assays.  
3.2.2 Generation of hiN cells from hEFs using a subtractive screening 
approach 
Through the analysis of the expression of the neuronal marker βIII-tubulin (βIII), 
it was possible to determine the number of iN cells being formed, by quantifying the 
number of βIII-positive cells per mm2. The generation of GABAergic hiN cells was also 
quantified, through the expression of GABA in the converted cells. In order to assess a 
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possible expression of striatal markers in the GABAergic hiN cells, DARPP-32 expression 
was also investigated. This molecule is localized to neurons containing dopamine  
 
 
 
Figure 11 – The transcription factors’  combination.   
After grouping the transcription factors into four different groups (Conversion factors, factors 
involved in striatal medium spiny neurons’ development, factors involved in striatal development 
and brain and CNS-specific factors), they were used in different combinations: (A) each one of the 
groups was tested individually; (B) a combination containing all the groups together was also 
tested; (C) different combinations of three groups per condition were made. 
 
receptors (Gould and Manji, 2005), and is a commonly used marker for striatal neurons.  
Due to technical reasons, the analysis of βIII and GABA expression in the cells was 
performed in only one of the three replicates, per condition. No or very low levels of 
GABA- or βIII-expressing cells were found in the negative controls (less than n=0.04). No 
DARPP-32 expression was detected in any of the tested conditions.  
When analyzing the number of βIII-positive cells/mm2, the highest value was 
obtained in the condition where all the thirteen TFs were used to transduce hEFs 
(n=115.0). Group 1 also gave rise to a high number of converted cells per mm2 (n=88.9) 
and when excluding these transcription factors (ABM) from the infection pool, almost no 
conversion was detected (n=0.07) (Figure 12, B). None of the other individual groups of 
transcription factors were able to convert hEFs in the same extent than Group 1 (n=0,14, 
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n=0,09 and n=0,08, for groups 2, 3 and 4, respectively). These results showed that when 
Group 1 was present in the infection pool, a robust hiN generation was obtained in 
different conditions, with similar levels of βIII-positive cells. 
We also set out to determine if another quantification method could be used to 
access the efficiency of this conversion. In order to explore this question, the average 
percentage of converted cells, relatively to the number of DAPI+ cells was also calculated. 
According to this, we verified that even though the proportions were not exactly the same, 
similar observations could be made, by using this method (Figure 12, C).  
 
 
Figure 12 – First  attempt to convert  hEFs into striatal  hiN cel ls  by using a 
subtractive screening approach.   
(A) Fluorescence microscopy image (20x) showing a GABA-expressing cell (grey), among several 
βIII-tubulin-expressing converted cells (green) (Groups 1,2,3,4); (B) Number of βIII+ cells per 
mm2, per condition. 30-36 representative pictures were taken per well (condition), the total 
number of βIII+ cells was counted in these images and the total number of neurons per well was 
determined, as well as the number of neurons/mm2. In the case of the conditions comprising the 
A) 
B) C) 
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individual groups of transcription factors 2,3,4, the exact number of βIII+ cells was determined, 
due to a very low number of converted cells; (C) Average percentage of converted cells (Mean± 
SD). 30-36 representative pictures were used to determine the percentage of βIII+ cells per picture, 
relatively to the number of DAPI+ cells.  
3.2.3 Effect of different TF groups on GABAergic hiN formation 
After analyzing the βIII expression in the generated hiN, the GABA expression was 
also determined in these cells. According to this, the combination that allowed for the 
generation of the highest number of GABA-expressing cells was the one that comprised 
the four groups together (n=49). All the groups, except group 4 (n=0), showed an ability to 
generate GABA-expressing cells individually. When having the three-group combination 
per condition, the only condition in which no GABA-expressing cells were detected was 
the one where group 1 was missing. When omitting group 4 from the infection, the 
greatest decrease (n=8) regarding total number of GABAergic hiN cells compared to the 
combination of groups 1-4 (n=49) was observed (Figure 13, B). A smaller decrease in total 
GABAergic hiN was found when leaving out either group 3 or group 2. All the previously 
determined values also allowed us to determine the percentage of generated GABA-
positive neurons out of converted βIII-positive cells (Figure 13, C). The obtained 
percentages were in the range of 0.04% (in the absence of TFs from group 4) and 0,24% (in 
the presence of all the groups of TFs).  
 
 
Figure 13 – GABAergic hiN cells ’  quantif ication (f irst  round of  infections).   
(A) Fluoescence microscopy image (20x, cropped), showing a GABAergic hiN cell (Groups 
1,2,3,4); (B) Number of GABA-positive cells, per condition; (C) Percentage of GABA-positive cells 
relatively to the number of βIII+ cells, per condition (n=1). 
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3.2.4 A high variability affected the reproducibility of the results 
To access the reproducibility of the protocol and the obtained results, a second 
round of experiments was carried out according to the previously described screening 
approach and the quantification of the βIII- and GABA-expressing cells was determined 
according to previously described quantification methods, per condition. Additionally, in 
order to investigate a possible striatal phenotype in the generated hiN, the expression of 
Isl1, which is expressed in all differentiating striatal neurons until birth (Stenman et al., 
2003), was also investigated. 
For each one of the studied parameters, two of the replicates were used for 
quantification. Similarly to the previous round of experiments, rare or non-existing βIII- 
and GABA- expressing cells were observed in the untransduced controls. No Isl1-
expressing cells were detected.  
A high variability was observed in the values obtained through the quantifications 
among different wells within the same conditions. Additionally, the levels of βIII- and 
GABA-expressing cells appeared to be very different from the ones obtained in the 
previous infections’ round. 
Fifteen days after transgene activation, the expression of βIII in the reprogrammed 
cells was quantified. Contrarily to what was verified in the previous round of experiments, 
the condition that gave rise to the highest number of βIII-positive cells per mm2 was the 
one in which group 1 was used to reprogram the cells individually (n=10.5±4.2). When 
group 1 was not present in the combination, no conversion was detected (n=0) (Figure 14, 
B).  
The analysis of GABA expression in the generated hiN cells revealed that the 
highest number of GABA-expressing cells was obtained when all the groups of factors 
were present in the pool (n=300.0±144.2) (Figure 5, C). When the TFs from group 4 were 
not present, the highest decrease in the generation of GABAergic cells was achieved 
(n=139.5±31.8) (comparatively to the one obtained with groups 1,2,3,4). Similarly, the 
only condition that did not show to be able to generate GABA-positive cells was the one 
where group 1 was missing (Figure 15, B). 
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Figure 14 – Second subtractive screen for striatal  hiN cel ls .   
(A) Representative images of nine different TFs group combinations used to generate βIII- and 
GABA-expressing hiN cells (40x). As a reference for neuron morphology and expression of the 
markers, a primary culture of human cortex was used (control); (B) Number of βIII-positive cells 
per mm2. Combined results obtained from two wells (Mean±SD). 
 
 
 
 
 
Figure 15 – GABAergic hiN cel ls ’  quantif ication (second round of  infections).   
Fluorescence microscopy picture (40x, cropped), showing two GABAergic hiN cells (Group1); (B) 
Total number of GABA-positive cells, per condition. Combined results obtained in 2 wells 
(Mean±SD); (C) Percentage of GABA-positive cells, relatively to the total number of converted 
cells (βIII-positive) (Mean±SD, n=2). 
 
The results from the first round of infections suggested that group 1 was required 
for the generation of cells expressing the neuronal marker βIII. We decided to additionally 
combine the different groups of TFs pairwise, always including group 1 in the 
combination. The obtained results did not give us any additional information, but 
demonstrated that when group 1 was combined with group 4, the highest number of 
GABA-expressing cells was obtained (Figure 16, C), confirming the presence of potentially 
important genes in pool 4. 
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Figure 16 – Pairwise combination of  the groups containing the thirteen 
transcription factors.  
(A) Representative images of the wells, where different pairwise combinations were used to infect 
hEFs, generating βIII- and GABA-expressing hiN cells (40x). As a reference for neuron 
morphology and markers’ expression, a primary culture of human cortex was used (control); (B) 
and (C) Number of βIII-positive cells per mm2 and corresponding total number of GABA-positive 
cells, obtained in the pairwise combinations of the TF groups (Mean±SD, n=2). 
 
3.3 Investigating the efficiency of different differentiation 
protocols in the generation of hiN cells  
3.3.1 Experimental design 
As the previously presented results show, we could successfully convert hEFs into 
hiN cells. However, the generation of those cells was variable in frequency and sometimes 
conversion was low, which led us to ask whether it would be possible to promote an 
increase in the stability of conversion and in the yields of generated converted cells, by 
using a different protocol. Therefore, five different protocols were tried to access their 
potential in the generation of hiN cells from hEFs. 
The first condition includes the use of the SM and a characteristic cocktail of 
neurotrophic factors, as described by Ladewig et al. (Ladewig et al., 2012). In order to 
compare the yields of generated cells, we also included a condition with the delayed 
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doxycycline protocol (Condition II) used in the previous experiments of this project, and a 
condition in which a protocol with no delay in doxycycline was used, similarly to previous 
studies performed in the lab (Pfisterer et al., 2011a) (Condition IV). Finally, we then 
combined the protocols used in condition I and II, aiming to investigate if any synergistic 
effect of the use of these two protocols together could be observed (conditions III and V). 
The difference between these two conditions is that they involve the use of a different 
cocktail of neurotrophic factors, along with the use of SM and a delay in doxycycline 
delivery to the cells. 
 
 
Figure 17 -  Schematic  representation of  the t imelines for the f ive different 
differentiation protocols  (conditions). 	  	  
Here, the conditions I and IV are grouped together, since they last the same (30 days). For the 
same reason, the conditions II, III and V, which include a delay of six days until the adding of 
doxycycline, are also grouped (they last 36 days).  
 
I 
IV 
II 
III 
V 
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 We tested the five different protocols in cells infected either with the conversion 
factors ABM or with AN (except for condition V, in which the factors AN were not 
tested). 
For each one of the conditions, three replicates were made (except for infections 
with AN, in which n=2) and the converted cells were quantified by high content analysis 
(described in 2.7) following Immunocytochemistry assays. Similarly, the protocols were 
also tested in untransduced cells (negative controls). Two different timepoints were 
analyzed: day 15 and day 23, post transgene activation. For the conditions II, III and V, 
which involve a longer period of culture due to the delay in doxycycline, the cells from the 
second timepoint were analyzed at day 21 instead of 23, due to observed cell death. 
 
3.3.2 Different effect of the tested protocols in the generation of hiN cells 
   Eleven days after infection of the hEFs with the factors ABM and AN, it was 
already possible to observe some differences in the cultured infected cells. Under the 
microscope, cells that resembled neurons were observed, and when looking to the cells 
infected with ABM, clear differences in the number and morphology of the cells were 
visible (Figure 18). 
 
 
Figure 18 – Bright f ie ld microscope pictures of  ABM-infected hEFs,  e leven days 
after  infection.  
The hereby shown pictures were taken eleven days after infection, i.e., for conditions I and IV, ten 
days after transcription activation, and for conditions II, III and V, four days after transcription 
activation. Cells infected with ABM (upper, 10x; lower, 20x magnification). 
 
Fifteen days after transgene activation, hEFs treated according to conditions I-V 
were fixed and stained for further analysis and quantification. Through the expression of 
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the neuronal marker MAP2, it was possible to analyze the number of generated hiN cells 
(MAP2-expressing), and to determine the percentage of converted cells in culture. 
Additionally, and since changes in cell numbers during the process of conversion may 
contribute to the overall conversion efficiency, we also determined the conversion 
efficiency as suggested by (Vierbuchen et al., 2010), which allows determining the 
percentage of MAP2-positive cells in relation to the initial number of plated cells. The 
three replicates were used for this purpose. Similarly, in one of the replicates, the 
generation of GABAergic hiN cells was quantified through the analysis of GABA 
expression in these cells, when infected with ABM. For technical reasons, it was not 
possible to analyze the expression of GABA in hiN converted from hEFs through infection 
with AN. 
Some MAP2-positive and GABA-positive events were detected in the 
untransduced controls (an average of 2.5% and 0.2% of the total, respectively). 
When observing the cells through fluorescence microscopy, it was possible to 
observe not only differences in the cell number, but also in cell morphology, when 
comparing the different conditions (Figure 19, A). Condition III gave rise to the highest 
percentage of MAP2-positive cells (of the total DAPI-positive), either when infecting the 
cells with ABM or AN. However, the infection with ABM gave rise to the highest 
percentage of MAP2-positive cells, when compared with AN, already on day 15 
(n=22.9%±3.2% for ABM and 11.3%±0.0% for AN) (Figure 19, B and C). It seems that the 
use of the factors ABM in the infection of the hEFs, in general, leads to a higher efficiency 
in the hiN generation, for all the conditions. When analyzing the conversion efficiencies 
(in relation to the number of plated cells) obtained in condition III, at day 15 after 
transgene activation, that becomes also clear (n=121.7%±21.5% for ABM and 56.3%±0.0% 
for AN) (Figure 20). 
The results obtained in condition III show that the combination of the protocols 
used in conditions I and II gives raise to a synergistic effect in the generation of MAP2-
positive hiN cells. None of the two conditions, by themselves, was able to give rise to the 
same yield of converted cells than condition III. 
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Figure 19 – Different effect  of  the tested differentiation protocols ,  in the 
generation of  hiN cel ls .    
(A) Fluorescence microscopy pictures, from the different tested conditions (I-V) and positive 
control (human cortex). Cells infected with ABM and fixed 15 days after transgene activation (20x 
magnification). For all the conditions, it was possible to observe hiN cell generation (MAP2-
positive cells); (B) and (C) Percentages of MAP2-positive cells, out of the total number of cells in 
culture (DAPI-positive), per condition (Mean ± SD), when hEFs were infected with ABM and AN, 
respectively. 
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Figure 20 – Conversion eff iciencies (%),  per condition.  
Conversion efficiencies obtained for the conditions I-V, when hEFs were infected with ABM (on 
top) or AN (bottom), calculated for cells fixed 15 days after transcription activation (Mean±SD). 
 
The lowest percentages of MAP2-positive cells and conversion efficiencies were 
obtained when testing the protocols of conditions II and IV. The percentages of hiN cells 
were only slightly superior for condition II (delayed doxycycline, no SM) (n=3.4%±1.1%) 
when comparing with condition IV (no delayed doxycycline, no SM) (1.0%±0.7%), upon 
infection with ABM (Day 15) (Figure 19, B). 
When comparing conditions which differed only in the cocktail of neurotrophic 
factors used along the differentiation protocol, condition III shows to be able to generate a 
higher percentage of hiN cells, either with ABM (n=22.9%±3.17%, for day 15 after adding 
doxycycline) or AN (n=11.3%±0.0%, day 15), than condition V (n=7.5%±1.2% for ABM 
and n=0.7%±0.5% for AN, day 15). The conversion efficiencies also show these differences 
(Figure 20). 
During the experiment, from the first to the second timepoint, an overall decrease 
in cell number was observed, especially when the protocols involved the use of SM. When 
comparing the total number of cells between the first (day 15) and second timepoints (day 
21/23), a decrease in the range of 43.7% and 56.1% (data not shown) for all the conditions 
involving the use of SM (condition I, III and V), was observed when infecting the cells 
with ABM. When using the TFs AN, these were in the range of 41.2% and 49.4% 
(conditions I and III). In conditions that do not involve SM in the protocol, the decrease in 
cell number was lesser (n=8.44% for condition II, with ABM; for condition IV with ABM 
and II with AN, there was an increase in the overall number of cells, between the two 
timepoints). 
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Figure 21 – Differences in hiN cell  morphology in two different t imepoints.  
Fluorescence microscopy pictures (20x), showing hiN cells (MAP2-positive) generated through the 
use of the protocol according to condition III, and ABM for the infection, in two different 
timepoints (day 15 and day 21). 
 
Despite the cell death that occured, when comparing the morphology of the 
obtained hiN cells, in two different timepoints, the cells that were fixed 21/23 days after 
culture seemed to have longer branches, and to resemble a more mature neuron 
morphology, when observed through fluorescence microscopy (Figure 21). 
 
3.3.2 Different protocols give rise to distinct numbers of GABAergic cells 
when infected with ABM 
When analyzing the expression of GABA in the converted hiN cells obtained from 
ABM-infected hEFs, GABA+/MAP2+ cells were observed in all the tested conditions (I-V). 
In Figure 22 (A), an example of GABAergic cells among the converted MAP2-positive 
cells is shown. 
Moreover, the numbers of GABAergic hiN cells yielded by the different conditions 
were different. Already at day 15, the results obtained in conditions III (n=1651) and V 
(n=3659) showed that the use of SM along with the delay of doxycycline, highly increases 
the number of GABA-expressing hiN cells. Contrarily, conditions I, II and IV, yielded 
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lower numbers of GABAergic hiN cells (n=440, n=358 and n=55, for respectively) (Figure 
22, B). When comparing the two different timepoints, there is an overall decrease in the 
number of converted GABA-expressing cells, except for condition IV, in which it was 
possible to observe an increase in the number of those cells, from day 15 to day 23 
(n=233.8). 
 
 
 
Figure 22 – GABAergic hiN generation when using different differentiation 
protocols .  
(A) Fluorescence microscopy picture (20x) showing GABAergic cells (red), among several MAP2-
positive hiN cells (day 15, condition III; resulting from ABM-infected hEFs); (B) Number of 
GABA-positive neurons, per condition, in two different timepoints (Mean; n=1).  
 
The results from this experiment suggest that the combination of a delay in the 
doxycycline-regulated transcription activation of the transgenes and the use of SM highly 
increases the yields of hiN cells and GABAergic hiN cells. The combination of factors 
ABM seems to be more efficient in the conversion of the cells than AN. 
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4.1 Validation of LentiStria vectors by qRT-PCR 
 
During this project, nine of the ten lentiviral vectors carrying the transgenes that 
encode the striatal transcription factors were successfully validated, by overexpression in 
both human 293T and mouse NSE14 cells, and by analysis of a dose-dependent increase in 
their expression by qRT-PCR. However, and for reasons that remain unknown, the 
construct carrying the CTIP2 transgene could not be validated by using this same 
approach.  
Our results indicate that the construct sequence is correct and therefore, due to the 
fact that background expression was detected in the untransduced human 293T control 
cells, a different cell line was transduced, the NSE14 cell line (mouse). The same problem 
was found, which led us to question the specificity of our primers and therefore to align 
the mouse and human CTIP2 sequences. The result from this alignment (data not shown) 
demonstrated that the two sequences are highly similar, not allowing for the design of 
primers with high specificity for the human sequence, and therefore, there is the 
possibility of a problem in the detection of the transgene. However, special attention to the 
design of several different primer pairs was paid, and no improvement in the detection of 
an increase of CTIP2 expression was observed. Also, a possible explanation for the lack of 
dose-dependent expression of this factor could be in the fact that the amount of viruses 
used to transduce the cells was not enough for its detection.  
Those questions remain unanswered, and future experiments need to be done to 
assess the problem found during validation of the construct. In this attempt, a possible 
next step would be to analyze in a gel, after PCR, the different cDNA samples, that were 
synthesized for use in the validation qRT-PCR assay, from the different transduced and 
untransduced 293T and NSE14, and see if it is possible to detect a CTIP2 fragment. 
4.2 Generation of hiN cells  and screening for factors that could 
direct them towards a striatal  neuron phenotype 
 
To investigate the use of thirteen transcription factors in the possible generation of 
neurons with a striatal phenotype, a group-subtractive screening approach, which has 
proved to be effective in other study (Kim et al., 2011), was applied. The use of such 
approach allows for screening the factors based on their biological functions and patterns 
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of expression, since the factors are grouped according to those features, and for a faster 
and less virus-consuming screening than the one that could be made by removing the 
factors one by one from the infection pool. 
 During the screening, the important role of the ABM factors (Group 1) for 
generation of hiN cells was clear. In both rounds of experiments, when excluding Group 1 
from the infection pool, no or almost no neuron formation was detected, and when 
included, it gave rise to one of the highest detected portions of neurons in both rounds of 
experiments. 
The use of an additional cocktail of transcription factors with the ABM factors 
seems to have a positive effect in the generation of GABAergic hiN cells, since there was an 
increase in the number of those cells, when comparing only with ABM. 
Already in the first round of infections, Group 4 seemed to have an important role 
in the generation of GABAergic cells, since the lack of these factors in the infection pool, 
led to the highest decrease in the number of GABA-positive neurons. The significance of 
this group was reinforced by the additional data from the second round of experiments. 
When the groups were organized pairwise, the combination of groups 1,4 was able to 
generate the highest number of GABAergic cells, compared to the values obtained with the 
combinations 1,2 and 1,3. 
The transcription factors from Group 1  (Ascl1, Brn 2 and Myt1L) are proved to be 
involved in processes related with neuronal commitment and differentiation 
(www.ncbi.nhm.nih.gov/gene/429), regulation of gene expression during neurogenesis 
(Atanasoski et al., 1995; Schreiber et al., 1993) and found at early stages of neuronal 
differentiation (Armstrong et al., 1995; Kim et al., 1997). While the transcription factors 
from group 4 (Gli 1, Otx2, FoxG1 and Gsx1) are related with forebrain development, gene 
regulation during proliferation and differentiation, and they are involved in brain 
development. It seems likely that functions related to these processes are important for the 
generation of GABAergic hiN cells. 
 Even not resulting in the generation of neurons with striatal markers’ expression 
(DARPP-32 and Isl1), these experiments were very valuable, leading us to the 
determination of which transcription factors could be more important for the generation 
of GABAergic hiN cells. Similarly to the direct conversion of human fibroblasts into 
dopaminergic neurons, in which these iDA cells were rare events, in initial screens, also 
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the possibly arising striatal GABAergic cells could be. Therefore, a high level of GABA-
positive events also increases the probability of striatal markers’ occurrence. 
 Future studies involving gene expression analysis in the generated cells would also 
be necessary to confirm the observed phenotypes and to exclude the fact that striatal 
markers are not expressed at all in these cells. It would also be interesting to understand 
which genes are being up- and down-regulated during the process of reprogramming, 
using the selected cocktail of factors.  
Due to the high variability among the results, we cannot draw conclusions 
concerning the screening for determining the minimal number of TFs for the generation 
of striatal hiN cells by using factors belonging only to groups 1 and 4. More experiments 
would be needed to address the reasons and possible solutions for such variability. It is 
likely that the use of different lentivirus batches in the two experiments could affect the 
conversion of the hEfs and possibly, the resulting data. 
4.3 Investigation of the best protocol for converting hEFs into 
hiN cells  
 
After successfully converting hEFs into hiN cells, we next performed a comparative 
study, involving different differentiation protocols, in order to investigate which one could 
lead to an improvement in the generation of these iN cells.  
A protocol that combines the use of a delay in doxycycline, responsible for the 
transgenes activation in the cells, and SM (CHIR, SB and Noggin) with the use of a specific 
cocktail of transcription factors, as suggested by (Ladewig et al., 2012) (Condition III), 
gave rise to the highest percentage of MAP2-positive hiN cells. The results strongly suggest 
that there is a synergistic effect when combining the two different protocols (conditions I 
and II), since none of these protocols was able to generate similar percentages to those 
observed in condition III. Furthermore, when observing the cells obtained in condition III 
at the microscope, they seemed to be more developed morphologically, presenting a 
higher number of branches. 
When comparing the results obtained in the conditions that gave rise to the lowest 
percentages of hiN cells, conditions II (with delay in doxycycline, no SM) and IV (no delay 
in doxycycline, no SM), it seems that the delay in doxycycline does not add a significant 
effect in the generation of hiN cells, since there is only a slight increase in the percentage 
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of MAP2-expressing hiN in condition II, when compared with condition IV.  By using a 
delay in doxycycline, an increase in the conversion efficiency is expected though, since the 
transduced cells keep proliferating for six days, increasing the number of cells that express 
the genes that will allow for conversion, when transcription is activated. 
The use of the cocktail of neurotrophic factors suggested by (Ladewig et al., 2012), 
which includes the use of NT3, BDNF, GDNF and d-cAMP , also seems to positively affect 
the survival of generated converted cells, which can be observed when comparing the 
results obtained in conditions III and V.  
When analyzing these results (described in 3.3), and the results from previous 
infection rounds (performed for screening of striatal TFs, described in 3.2), and 
comparing the obtained conversion efficiencies (Figures A4, A5 and 20), the effects of 
using the protocol of condition III also become clear. In the first and second round of 
infections, conversion efficiencies of approximately 80% and below 10%, respectively, were 
obtained (Figures A4 and A5). And when using the protocol of condition II for conversion 
of hEfs into hiN with the ABM factors (Figure 20, upper graph), a conversion efficiency of 
approximately 27% was achieved. Therefore, by comparing those values with the 
conversion efficiencies obtained by applying the protocol of condition III, a great 
improvement was made. Furthermore, this protocol also allows for an increase in the 
number of observed GABAergic hiN cells. 
An analysis of the average number of DAPI-positive cells found in the two 
different studied timepoints (day 15 and 21/23) (data not shown) revealed that there was a 
decrease in the number of cells in a range between 40 to more than 50% in conditions 
involving the use of SM (conditions I, III and V). However, the reasons for this decrease 
are still unknown. This could be due to cell death or detachment, or simply due to the 
occurrence of less proliferation. 
Taken together, the results show that the most advantageous protocol for hiN 
generation is the one from condition III, and that this protocol is more effective when 
using the TFs ABM for infecting the hEFs. By analyzing the conversion efficiencies of 
these conversions, which relate the number of hiN cells with the number of plated cells, it 
is possible to observe values close to 100%, while with the conversion factors AN, 
conversion efficiencies below 60% were observed.   
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Although some complementary studies must be done and repetition of the assays is 
needed, it is possible to draw some main conclusions from the studies performed during 
the course of this project. 
 
First, the different groups of TFs selected to perform the screening for striatal 
GABAergic projection neurons’ formation were all able to generate hiN cells, but none of 
them generated yields of converted cells as the ones obtained with the conversion factors 
factors ABM (group 1). And through the analysis of the results obtained in both rounds of 
infection, it is possible to conclude that the TFs ABM are essential an efficient generation 
of hiN cells from the infected fibroblasts. Furthermore, the results obtained during the 
evaluation of different protocols for the generation of the hiN cells showed that infecting 
the cells with the TFs ABM is more effective than with another combination of TFs, also 
able to generate neurons (AN). 
 
 Second, the addition of striatal TFs to the ABM combination did not result in hiN 
cells that express the striatal markers DARPP-32 or Isl1, which was analyzed by 
Immunocytochemistry assays, but affects the yields of GABA-expressing hiN cells, 
increasing them. 
 
 Third, the TFs present in group 4 (Gli1, Otx2, FoxG1 and Gsx1) revealed to have 
an important role in the generation of GABAergic cells, since the lack of these factors in 
the infection pool led to the highest decrease in the number of GABAergic cell, compared 
to the values obtained when other groups were lacking. The importance of this group was 
revealed already in the first round of infections, and reinforced in the second, when 
analyzing the results from the pairwise combination of the four different groups of TFs. 
 
Also, the use of a differentiation protocol for the conversion of hEFs into hiN cells 
that includes both a delay in the deliver of doxycycline in the cells and the use of small 
molecules, as well as a specific cocktail of neurotrophic factors, is more effective in the 
generation of hiN cells as well as in the generation of cells with GABAergic phenotype,  
than the ones that do not include a delay in doxycycline and/or the use of small molecules. 
Therefore, future studies involving direct conversion of fibroblasts into neuron-like 
converted cells could benefit from the use of this new protocol. 
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Table A1 – The transcription factors selected to perform the screening,  their  
biological  roles  and patterns of  expression.   
Thirteen transcription factors involved in neuronal development and differentiation of striatal 
neurons, with distinct patterns of expression were sorted out into four different groups. 
In Group 1 are the conversion factors, Ascl1, Myt1L and Brn2, known by their capacity to 
convert fibroblasts into neurons (Vierbuchen et al., 2010). In Group 2 were grouped CTIP2, Isl1 
and Nolz1, which are involved in the striatal  medium spiny neurons’  development 
specifically, while in Group 3, Dlx2, Dlx5 and Gsx2, TFs that seemed to be related to the striatal  
development.  Finally, on group 4, the TFs Gli1, Otx2, FoxG1 and Gsx1 that were grouped 
together since they are considered as specif ic  and related to early  CNS development.  
Official name 
Also 
known as 
Superclass/cl
ass 
Involved in 
G
ro
up
 1 
Ascl1 
Ash1; 
Hash1; 
Mash1; 
bHLHa46 
Basic-helix-
loop-helix 
(bHLH)/bHLH 
Neural commitment and differentiation 
(http://www.ncbi.nlm.nih.gov/gene/429). 
 
POU3F2 
Brn2; Oct7; 
Otf7; 
POUF3 
Helix-turn-
hélix/Homeo 
domain 
Mammalian neurogenesis through the 
regulation of their diverse patterns of gene 
expression (Atanasoski et al., 1995; Schreiber et 
al., 1993). 
Myt1L 
Myt1-L; 
NZF1; 
KIAA1106. 
Zinc-
coordinationg 
DNA-binding 
domains/Cys2
His2 zinc finger 
domain 
Development of neurons in the mammalian 
CNS, suggested by the developmental 
expression and localization of this protein. 
Found in neurons at early stages of 
differentiation (Armstrong et al., 1995; Kim et 
al., 1997). 
G
ro
up
 2 
BCL11B 
CTIP2; 
CTIP-2; 
RIT1; 
ZNF856B; 
hRIT1-alpha 
Zinc-
coordinationg 
DNA-binding 
domains/Cys2
His2 zinc finger 
domain 
Controls the differentiation of medium spiny 
neurons and the establishment of the cellular 
architecture of the striatum (Arlotta et al., 2008). 
Is l1  Isl-1; Islet1; Islet-1 
Helix-turn-
helix/Homeo 
domain 
Generation of motor neurons (Pfaff et al., 1996). 
Without it, there is no neural tube motor 
differentiation 
(http://www.ncbi.nlm.nih.gov/gene/3670).  
It has been reported in the developing striatum. 
Expressed in striatal precursors (Wang and Liu, 
2001). 
ZNF503 
Nolz-1; 
MGC2555; 
FLJ45745 
Zinc-
coordinating 
DNA binding 
domains 
Striatal neurogenesis through the regulation of 
retinoic acid signaling (Urban et al., 2010). 
Expressed in differentiating progenitors of 
striatal projection neurons (Chang et al., 2004). 
G
ro
up
 3 
D lx2 Tes-1; Tes1; Dlx-2 
Helix-turn-
helix/Homeo 
domain 
Forebrain and craniofacial development 
(http://www.ncbi.nlm.nih.gov/gene/1746). 
Characteristic protein in the developing 
striatum and striatal neural stem cells 
(Willaime-Morawek et al., 2006). Its expression 
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defines distinct stages of basal forebrain 
differentiation (Eisenstat et al., 1999). Dlx1 and 
2 and Ascl1 control striatal patterning and 
differentiation through parallel and overlapping 
pathways (Long et al., 2009). 
Dlx5  
Helix-turn-
helix/Homeo 
domain 
Forebrain and craniofacial development 
(http://ncbi.nlm.nih.gov/gene/1746). Its 
expression defines distinct stages of basal 
forebrain differentiation (Eisenstat et al., 1999). 
Gsx2 Gsh-2; Gsh2 
Helix-turn-
helix/Homeo 
domain 
Development of GABAergic neurons 
(Kurokawa et al., 2005). Its function has been 
reported to be essential for maintaining the 
molecular identity of early striatal progenitors 
(Toresson et al., 2000). Expressed in precursor 
cells, from which, during the embryonic period, 
many olfactory bulb neurons arise from the 
lateral ganglionic eminence (Vergano-Vera et 
al., 2006).  
G
ro
up
 4 
G l i1  Gli 
Zinc-
coordinating 
DNA-binding 
domains/Cys2
His2 zinc finger 
domain 
Development and it is a known oncogene (Liu et 
al., 1998), regulating stem cell proliferation. 
Expressed during mouse embryo development 
in forebrain, midbrain and cerebellum (Hui, 
1994; Walterhouse et al., 1993). Some of the 
downstream gene targets of human Gli1 include 
regulators of the cell cycle and apoptosis (Yoon 
et al., 2002). 
Otx2 MCOPS5; MGC45000 
Helix-turn-
helix/Homeo 
domain 
Brain and sensory organ development. A similar 
protein in mice is required for proper forebrain 
development 
(http://www.ncbi.nlm.nih.gov/gene/5015). 
Expressed in the developing mammalian brain 
(Rath et al., 2006). 
FoxG1 
BF1; BF2; 
QIN; FKH2; 
HBF2; 
HFK1, 
among 
others 
Helix-turn-
helix/Fork 
head/winged 
helix 
Regulation of the expression of some genes that 
are involved in cellular growing, proliferation, 
differentiation and longevity. Important for 
embryonic development (Tuteja and Kaestner, 
2007). It may play a role in the development of 
the brain and telencephalon 
(http://www.ncbi.nlm.nih.gov/gene/2290). 
Gsx1 Gsh-1; Gsh1 
Helix-turn-
helix/Homeo 
domain 
Brain development, suggested by its expression 
in several discrete domains of the developing 
brain, including the diencephalon, which gives 
rise to the thalamus and hypothalamus. Its 
transcription is restricted to the CNS (Valerius 
et al., 1995). 
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Figure A2 -  Schematic  representation of  the cloning strategy for the 10 striatal  
Transcription Factors (TFs).   
The ten TFs were cloned into the LV #1000-hPGK. The ORFs of eight transcription factors (Dlx2, 
Dlx5, Gsx1, Gsx2, FoxG1, Isl1, CTIP2 and Nolz1) were cut with the proper restriction enzymes 
and directly ligated into the LV#1000-hPGK vector plasmid. The Otx2 ORF sequence was 
amplified by PCR, gelpurified and then ligated into pCRII vector. Chemically competent bacteria 
were transformed with the cloning plasmid and suitable clones were identified by EcoRI 
restriction. After identifying the correctness of the insert by sequencing, Otx2 was cut out by 
SalI/BamH1 restriction and subsequently ligated into the linearized LV #1000-hPGK with 
454 AgeI (1)
448 SalI (2)
1453 SalI (2)
puc57_huDlx2 3715bp
3715 bp
huDLX2 NG_009219.1 466..1452
pUC19 1..1999
CMV\IE-I\prom 2217..2889
RU5 2891..3072
SK-LTR4 2989..3008
PBS\SL123 3073..3223
SL4\mgag 3224..3588
denvRF1 3588..3733
RRE 3734..3974
huDLX2 NG_009219.1 5157..6143
5145 AgeI (1)
hPGK 4622..5137
PPT 4459..4582
denvRF2 3976..4443
6144 SalI (1)
WPRE* 6150..6656
WPREsense 6508..6527
#1000ASMIRTseq 6747..6728
dR3RU5 6781..7014
SK-LTR4 6932..6951
SV40polyA\oriR 7215..7420
pUC19 7421..7581
phageF1\origin 7582..8040
#1000.huDLX2
8040 bp
 
Cut	  and	  ligate 
Dlx2	  –	  1005bp 
Dlx5	  –	  888bp 
Gsx1	  –	  813bp 
Gsx2	  –	  933bp 
FoxG1	  –	  1488bp 
Isl1	  –	  1068bp 
CTIP2	  –	  2703bp 
Nolz1	  –	  1977bp 
 
Sub-­‐cloning 
Gli1	  –	  3336bp 
Regular	   
Approach 
Otx2	  –	  870bp 
Puc57 
LV	  #1000-­‐hPGK 
Gli1 mus 336..3683
pCRII_Gli1mus
7319 bp
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corresponding ends. Gli1 was sub-divided into a larger fragment (Gli1 upper), containing 
SalI/BamH1 compatible ends and a smaller fragment (Gli1 lower) with two BamH1 compatible 
ends. Gli1 upper was cloned into the LV #1000-hPGK thereby reducing the number of BamH1 
restriction sites and subsequently, Gli1 lower was inserted into the same plasmid, following a sub-
cloning strategy. 
 
 
 
 
Figure A3 – Gel  picture showing the bands resulting from the digestion of  the 
LV#1000-hPGK-CTIP2 construct (9738bp) with the restriction enzymes BamH1, 
SalI  and MluI.   
The expected fragments for each digestion were: B (9374bp and 364bp), S (9738bp), M (8631bp 
and 1107bp), B/S (7035bp, 2339bp and 364bp), B/M (7229bp, 1107bp, 1038bp and 364bp), B/S/M 
(7035bp, 1107bp, 1038bp, 364bp, 194bp). 
 
 
 
 
L	  –	  Ladder	  (1Kb)	  
B	  –	  BamH1	  
S	  –	  SalI	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Figure A4 – Conversion eff iciencies obtained in the f irst  subtractive screen for 
striatal  hiN cel ls .  
The presented conversion efficiencies were calculated by relating the number of converted neurons 
with the number of plated cells, in each of the tested conditions (Mean; n=1). 
 
 
 
Figure A5 – Conversion eff iciencies obtained in the second subtractive screen for 
striatal  hiN cel ls .  
Similarly to the first screening round, also the presented conversion efficiencies relate the number 
of converted cells with the number of plated cells (Mean±SD; n=2). 
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